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ABSTRACT 
 
EMILY G. LOWERY-GIONTA: The Role of Corticotropin-Releasing Factor on Binge-Like 
Ethanol Consumption 
(Under the direction of Todd E. Thiele) 
 
Previous research establishes a crucial role for corticotropin releasing factor (CRF) in 
ethanol dependence. Recent evidence demonstrates a role for the CRF type 1 receptor 
(CRF1R) in the modulation of binge-like ethanol consumption by non-dependent animals, a 
behavior which can precede ethanol dependence. The goal of this dissertation was to 
further characterize the role of the CRF system in binge-like ethanol consumption. The role 
of the CRF receptors in binge-like ethanol consumption were pharmacologically investigated 
in Chapter 2. In Chapter 3, the effects of binge-like ethanol consumption on CRF expression 
was assessed using immunohistochemistry techniques. CRF is known to signal through two 
pathways, the hypothalamic pathway that activates the hypothalamic-pituitary-adrenal (HPA) 
axis response to stressors, and the extrahypothalamic pathway that includes limbic regions 
such as the amygdala, which is involved in drug-taking behaviors. Thus, in Chapter 4, the 
involvement of the HPA axis in binge-like ethanol consumption was assessed using a series 
of pharmacological and surgical techniques to manipulate HPA axis function and 
radioimmunoassay techniques to observe the effects of binge-like ethanol consumption on 
the HPA axis. Based on the results of previous chapters, in Chapter 5, the involvement of 
the central nucleus of the amygdala was assessed using immunohistochemistry, 
electrophysiology and pharmacology approaches to manipulate the CRF system. Results 
show that binge-like ethanol consumption by non-dependent animals selectively alters CRF 
signaling in the CeA, and that the CRF1R in this brain region is necessary for binge-like 
levels of ethanol intake to occur. In tandem with data suggesting that the CRF system does 
not modulate non-binge-like ethanol consumption, these observations suggest that binge-
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like ethanol consumption, like dependence-induced ethanol consumption, recruits the CRF 
system of the CeA. Therefore, we hypothesize that recruitment of the CRF system during 
binge-like ethanol consumption leads to transient neuroadaptations in the amygdala, and 
these changes in CRF signaling become permanent with repeated binges and eventually 
culminate in ethanol dependence. The implications of this hypothesis are discussed in the 
context of the leading theory of alcohol dependence. 
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 CHAPTER 1 
 
GENERAL INTRODUCTION 
 
 
 
 Alcohol is the result of a natural process of fermentation, by which sugars are 
converted in to carbon dioxide and ethanol by yeast (McKim 2003). Early forms of alcohol 
were most likely derived from honey or fruit, while ethanol derived from grains and grapes to 
make beer and wine became popular with the advent of agriculture in approximately 6000 
B.C. Alcohol use has been noted in many major ancient empires, including the Egyptians, 
Assyrians, Greeks and Romans. In the United States, ethanol use has a storied history that 
includes periods of debauchery and temperance (McKim 2003). The Eighteenth Amendment 
to the U.S. Constitution, perhaps better known as “Prohibition,” prohibited the 1to change 
alcohol use among the American population, and organized crime centered around alcohol 
rose to notorious levels. Fourteen years after it was enacted, Prohibition was repealed by 
the Twenty-First Amendment. 
 Since Prohibition, yearly surveys have shown that between 55 and 71% of the U.S. 
population has reported some form of alcohol use (NIAAA 2008). According to the most 
recent National Survey on Drug Use and Health, 83% of the U.S. population has used 
alcohol in their lifetime and 66% had consumed alcohol within the previous year (NIAAA 
2004). While estimates of non-heavy drinking tend to remain stable, alcohol 
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misuse has risen 1% in the past decade, and approximately 17.6 million American adults 
currently meet the diagnostic criteria for an alcohol use disorder (AUD; Grant, Dawson et al. 
2004). The societal costs associated with ethanol use have also risen steadily in the last decade 
(NIAAA 1999) and now exceeds $260 million dollars (White, Hingson et al. 2011). 
 The fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 
distinguishes between two major types of AUDs, alcohol dependence and alcohol abuse 
(American Academy of Family Physicians. and American Psychiatric Association. Work Group 
on DSM-IV-PC. 1995). Alcohol dependence is characterized by drinking more or longer than 
intended, showing difficulty reducing alcohol consumption, drinking despite adverse 
consequences, and spending a large amount of time drinking, thinking about drinking or 
recovering from drinking. Alcohol dependence is also characterized by the development of 
tolerance, in which higher doses of alcohol must be consumed to achieve the desired effects of 
the drug after chronic use. Perhaps the most telling symptoms of alcohol dependence are the 
presence of withdrawal symptoms (including increased anxiety, irritability, and stress 
responsivitiy) and elevated alcohol drinking to alleviate these symptoms. Alcohol abuse is 
defined as recurring alcohol use leading to any of the following consequences: inability to fulfill 
obligations, finding oneself in hazardous situations, legal problems or pervasive social and/or 
interpersonal problems. Though both alcohol abuse and alcohol dependence are nationwide 
health problems, alcohol abuse is of growing concern as the number of American adults who 
meet the criteria for alcohol abuse has risen in the past decade. Additionally, though FDA-
approved drugs for the treatment of alcohol dependence are now commonly prescribed (Anton 
and Swift 2003; Heilig, Thorsell et al. 2009), no pharmacological treatments have been 
developed to target alcohol abuse specifically. As a result, preclinical investigations are now 
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focusing on potential targets for the treatment of alcohol abuse in addition to alcohol 
dependence. 
Binge Drinking in the Human Population 
 A common form of alcohol abuse is generally known as “binge drinking,” an episode of 
drinking in which enough alcohol (ethanol) is consumed in a two hour period to generate blood 
ethanol concentrations (BECs) of 80 mg/dl or greater (Council 2004; Crabbe, Harris et al. 2011). 
A binge typically consists of 5 or more drinks and 4 or more drinks within two hours for adult 
men and women, respectively (Council 2004). Binge drinking is a common risk behavior among 
adolescents and adults (Enoch 2006; Miller, Naimi et al. 2007; Blazer and Wu 2009; Courtney 
and Polich 2009; Stahre, Brewer et al. 2009; Chowdhury, Balluz et al. 2010), and the U.S. 
Department of Justice estimates that 75% of all ethanol consumed in the United States is 
consumed in the form of a binge (Prevention 2005). Binge drinking is associated with numerous 
short-term (Bedford, O'Farrell et al. 2006; Miller, Naimi et al. 2007; Chamberlain and Solomon 
2008; Read, Beattie et al. 2008; Stahre, Brewer et al. 2009) and long-term (Athyros, 
Liberopoulos et al. 2007; O'Keefe, Bybee et al. 2007; Niccoli, Baca et al. 2008; Sull, Yi et al. 
2009) adverse consequences, including increased risks of driving under the influence (Flowers, 
Naimi et al. 2008) and developing numerous health conditions (Puddey, Rakic et al. 1999; 
Morch, Johansen et al. 2007; O'Keefe, Bybee et al. 2007; Fan, Russell et al. 2008). Despite 
these risks, binge drinking appears to be a persistent behavior, as those who binge drink in 
young adulthood are twice as likely as non-binge drinkers to binge drink during adulthood 
(Jefferis, Power et al. 2005). Perhaps most alarming is evidence suggesting that binge drinking 
may lead to ethanol dependence (Wechsler, Dowdall et al. 1998; Jennison 2004; McCarty, Ebel 
et al. 2004; Englund, Egeland et al. 2008; Laranjeira, Pinsky et al. 2009; Rubinsky, Kivlahan et 
al. 2009). Indeed, frequent binge drinkers are 19 and 13 times more likely than non-bingers 
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(who drank just as frequently but in moderation) to qualify for diagnoses of ethanol dependence 
and ethanol abuse, respectively (Knight, Wechsler et al. 2002), suggesting that the amount of 
ethanol consumed is an important factor in the development of AUDs. As such, an 
understanding of the neurobiological mechanisms that promote binge drinking would inform the 
treatment of AUDs, as recruitment of mechanisms thought to underlie ethanol dependence may 
occur during bouts of high ethanol drinking, including binges. 
Corticotropin-Releasing Factor 
Corticotropin-releasing factor (CRF) is a 41-amino acid poly-peptide that is widely 
expressed throughout the central nervous system (CNS) and modulates a range of 
neurobiological responses through activation of the Gs-protein coupled CRF type 1 (CRF1R) 
and type 2 (CRF2R) receptors (Gulyas, Rivier et al. 1995; Van Pett, Viau et al. 2000; Hauger, 
Risbrough et al. 2006; Heilig and Koob 2007).  While CRF binds to both receptors, it has greater 
affinity to the CRF1R (Ryabinin, Bachtell et al. 2002; Hauger, Risbrough et al. 2006; Pioszak, 
Parker et al. 2008). CRFRs are also stimulated by the 40-amino acid urocortin (Ucn) family of 
peptides, with Urocortin I (Ucn1) displaying equal affinity for both CRF1R and CRF2R, and 
Urocortin II (Ucn2) and Urocortin III (Ucn3) displaying affinity primarily for the CRF2R (Ryabinin, 
Bachtell et al. 2002; Venihaki, Sakihara et al. 2004; Hauger, Risbrough et al. 2006).  In rodents, 
expression of the CRF1R is ubiquitous throughout the brain, with high density found in 
hypothalamic, cortical, and limbic regions, while CRF2R expression is limited to specific regions, 
including the raphe nuclei, lateral septum, and subregions of the amygdala and hypothalamus 
(Hauger, Risbrough et al. 2006).  Agonist binding of these receptors induces distinct outcomes 
with respect to cellular signaling pathways, downstream mechanisms, and behavior (Hauger, 
Risbrough et al. 2006; Zhao, Valdez et al. 2007; Fu and Neugebauer 2008). Through actions as 
a neuromodulator, CRF is known to affect dopaminergic, glutamatergic and GABAergic 
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signaling throughout the brain (Hauger, Risbrough et al. 2006). CRF signaling through CRF1Rs 
and CRF2Rs has been implicated in a number of biobehavioral processes, including regulation 
of the hypothalamic-pituitary-adrenal (HPA) axis stress response, anxiety, depression, feeding, 
and excessive alcohol consumption (Latchman 2002; Ryabinin, Bachtell et al. 2002; Clark and 
Kaiyala 2003; Koob 2003; Hauger, Risbrough et al. 2006; Heilig and Koob 2007; Kozicz 2007). 
A growing literature suggests that the central CRFR signaling system exhibits plastic changes 
as ethanol dependence emerges (Koob 2003; Heilig and Koob 2007; Koob and Kreek 2007; 
Koob 2008), and CRF compounds have been shown to modulate dependence-induced ethanol 
consumption (Lowery and Thiele 2009). Given that CRF is involved in ethanol drinking during 
dependence, it is possible that CRF signaling also promotes binge-like drinking behavior prior to 
the onset of ethanol dependence. 
Preclinical Models of Ethanol Drinking and Binge-Like Drinking 
 Ethanol consumption has been modeled preclinically using methods that allow animals 
to voluntary self-administer ethanol or methods that involve forced ethanol exposure. Models of 
voluntary self-administration, such as two-bottle choice paradigms in which ethanol access and 
water access are given concurrently (O'Callaghan, Croft et al. 2002) or operant paradigms in 
which animals can choose to perform learned behaviors to obtain an ethanol reinforcer (Olive, 
Mehmert et al. 2000), allow for the investigation of the factors which underlie and/or promote 
ethanol self-administration. As many of these models do not promote consistently high levels of 
ethanol intake by rodents, they are suited for investigations of moderate ethanol consumption 
akin to “social drinking” by humans but are limited in their applications to investigations of binge-
like ethanol consumption, in which animals must achieve BECs of 80 mg/dl or higher in a period 
of 2 hrs (Crabbe, Harris et al. 2011). Models involving forced ethanol administration and/or 
exposure, such as ethanol administration by injection (Rivier and Lee 1996; Lee, Selvage et al. 
6 
 
2004) or oral gavages (Ogilvie, Lee et al. 1997; Ogilvie, Lee et al. 1998), may be tailored so that 
rodents receive high doses of ethanol and achieve BECs in excess of 80 mg/dl and thereby 
allow for the investigation of ethanol’s effects on the brain despite limitations in face validity.  
Investigations in recent history have combined the voluntary and forced administration 
approaches to assess the effects of consistent, chronic levels of ethanol consumption on later 
behaviors and neurobiology to model long-term ethanol use by humans. Chronic exposure to 
ethanol diet involves replacing animals’ normal food chow with a calorie-matched ethanol-
containing diet (Baldwin, Rassnick et al. 1991; Brown, Jackson et al. 1998; Breese, Knapp et al. 
2004; Breese, Overstreet et al. 2005). Chronic exposure to ethanol vapor involves exposing 
animals to high levels of ethanol via inhalation, often for long durations (Valdez, Roberts et al. 
2002; Becker and Lopez 2004; Sabino, Cottone et al. 2006; Finn, Snelling et al. 2007; Funk, 
Zorrilla et al. 2007). In these models, the levels of consumption and duration of exposure are 
controlled through forced administration, while the effects of such manipulations can be 
observed during times of self-administration. Both the ethanol diet approach and the ethanol 
vapor approach have been shown to increase subsequent ethanol consumption during self-
administration phases as compared to animals that have not undergone chronic exposure via 
ethanol diet or ethanol vapor (Schulteis, Markou et al. 1995; Schulteis, Hyytia et al. 1996; 
Brown, Jackson et al. 1998; Becker and Lopez 2004; Chu, Koob et al. 2007; Finn, Snelling et al. 
2007). Additional behavioral changes following chronic exposure to ethanol diet and ethanol 
vapor include enhanced stress responsivity and increased levels of anxiety upon withdrawal 
from ethanol (Menzaghi, Rassnick et al. 1994; Overstreet, Knapp et al. 2002; Valdez, Roberts et 
al. 2002; Breese, Knapp et al. 2004; Knapp, Overstreet et al. 2005; Overstreet, Knapp et al. 
2006; Knapp, Overstreet et al. 2007; Sommer, Rimondini et al. 2008). As ethanol-dependent 
humans also show these behavioral changes during ethanol withdrawal (Breese, Chu et al. 
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2005), chronic exposure to ethanol diet and ethanol vapor have been widely accepted as 
methods of inducing ethanol dependence. Neurobiological alterations following chronic 
exposure to ethanol diet or ethanol vapor have been the subject of several investigations, which 
show that a variety of neurochemical systems are altered by these procedures of ethanol 
administration, including the GABA, opioid and CRF systems (Koob 2003; Koob and Kreek 
2007; Koob 2008). While these models can force animals to achieve BECs in excess of 80 
mg/dl and are therefore valuable for understanding neuroadaptations following binge-like 
ethanol exposure, these models are limited in their ability to investigate the neurobiology that 
underlies and/or promotes binge-like drinking behavior.  
Recently, new preclinical models of ethanol consumption have been developed to elicit 
high levels of ethanol consumption via self-administration. These models, such as the 
“scheduled high alcohol consumption” paradigm and the intermittent access protocol, allow 
limited access to ethanol at specific times in a manner that generates high BECs (Crabbe, 
Harris et al. 2011). A similar model, called “drinking-in-the-dark” (DID), has been used 
extensively to study binge-like ethanol consumption by C57BL6/J mice, a strain that is known 
for its high ethanol preference (Rhodes, Best et al. 2005; Rhodes, Ford et al. 2007). This 4-day 
procedure involves giving mice access to a bottle containing 20% ethanol solution beginning 3-h 
into the dark portion of a 12h/12h light/dark cycle, a time of day when animals are active and 
typically consume food. On days 1-3 of the procedure, animals have access to ethanol for 2 hrs, 
after which ethanol is replaced with water. On day 4, which is considered the binge day, access 
to ethanol is extended to 4 hrs and blood samples are collected for analysis of BECs. Under 
these conditions, levels of ethanol consumption are reliably great enough to generate BECs in 
excess of 80 mg/dl and lead to evidence of physical intoxication, such as motor impairment 
(Rhodes, Best et al. 2005; Rhodes, Ford et al. 2007). Importantly, characterizations of this 
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procedure show that the high levels of ethanol consumption elicited by DID are not promoted by 
thirst (as concurrent ethanol and water access does not alter ethanol consumption) (Rhodes, 
Ford et al. 2007) or by caloric need (as manipulation of food availability and feeding peptides 
does not alter ethanol consumption) (Lyons, Lowery et al. 2008). Studies conducted to date 
have revealed roles for many neurochemical systems in binge-like drinking, such as GABA, 
dopamine, opioids, and acetylcholine, using the DID procedure (Crabbe, Harris et al. 2011). 
Emerging evidence also indicates that CRF is involved in binge-like ethanol consumption 
(Sparta, Sparrow et al. 2008), however, less is known about the brain regions that modulate 
binge-like drinking and the effects of binge-like drinking on behaviors associated with ethanol 
dependence (i.e., later ethanol drinking and anxiety). 
Ethanol and Corticotropin-Releasing Factor:  
Acute vs. Chronic Effects of Ethanol Exposure 
Converging evidence from numerous investigations suggests that the role of CRF in 
modulating the neurobiological effects of ethanol is dependent on the duration of exposure. 
Generally, initial or acute exposures to ethanol activate CRF in the hypothalamus, which 
activates the HPA axis stress response. Acute ethanol administration is accompanied by 
increases in levels of CRF (Li, Kang et al. 2005), CRF-like immunoreactivity (CRF-IR) (Redei, 
Branch et al. 1988), CRF heteronuclear RNA (hnRNA) and CRF messenger RNA (mRNA) 
(Rivier and Lee 1996; Lee, Selvage et al. 2004; Li, Kang et al. 2005), as well as increased 
CRF1R mRNA expression in the hypothalamus. Notably, no alterations in extrahypothalamic 
brain regions have been reported during the early stages of ethanol exposure. 
With chronic administration and withdrawal, ethanol induces further alterations in the 
CRF system, most of which are observed in limbic regions. Upregulation of CRF markers, 
including extracellular CRF, pre-pro CRF mRNA, and CRF mRNA have been reported in the 
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amygdala (Pich, Lorang et al. 1995), and more specifically, within the central nucleus of the 
amygdala (CeA) (Lack, Floyd et al. 2005; Funk, O'Dell et al. 2006; Sommer, Rimondini et al. 
2008) in dependent, ethanol-withdrawn rats relative to non-dependent controls.  Likewise, 
increased levels of extracellular CRF have been observed in the bed nucleus of the stria 
terminalis (BNST) (Olive, Koenig et al. 2002) and enhanced CRF mRNA expression has been 
noted in the paraventricular nucleus of the hypothalamus (PVN) after chronic ethanol exposure 
(Rivier, Imaki et al. 1990; Oliva 2007).  Additionally, increased CRF1R expression has been 
observed in the basolateral amygdala (BLA) and the medial nucleus of the amygdala (MeA) 
(Sommer, Rimondini et al. 2008), as well as the hypothalamus (Pickering, Avesson et al. 2007) 
in dependent, ethanol-withdrawn rats.  Decreases in CRF2R expression were observed in the 
BLA of ethanol dependent rats (Sommer, Rimondini et al. 2008), while increases have been 
observed in the dorsal raphe of mice (Weitemier and Ryabinin 2005), and the hypothalamus of 
rats (Pickering, Avesson et al. 2007) with a history of ethanol exposure.  
Such alterations appear to be functional, as marked changes in CRF-induced excitability 
in the BNST and CRF-induced inhibition in the CeA have been observed following prolonged 
exposure to ethanol (Nie, Schweitzer et al. 2004; for review, see Francesconi, Berton et al. 
2009; Nie, Zorrilla et al. 2009). Indeed, long-term investigations show that some of these 
neurobiological changes in CRFR signaling persist months into abstinence, which may 
contribute to the enhanced anxiety-like behaviors and stress responsiveness that are observed 
long after ethanol administration has ceased (Valdez, Roberts et al. 2002; Valdez, Zorrilla et al. 
2003; Breese, Chu et al. 2005; Zhang, Morse et al. 2007; Falco, Bergstrom et al. 2009), and 
follow-up investigations show that some of these changes can be normalized through 
reinstatement of ethanol self-administration (Olive, Koenig et al. 2002). Thus, the literature 
suggests that chronic ethanol exposure and withdrawal promote alterations in CRF signaling in 
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extrahypothalamic regions of the amygdala, the lateral septum, and the dorsal raphe, as well as 
the hypothalamus. These observations are consistent with the hypothesis that a dysregulation 
of CRFR signaling emerges over the course of ethanol dependence, and that this dysregulation 
may contribute to the excessive and uncontrolled ethanol intake associated with ethanol 
dependence (Koob 2003). The effects of ethanol on CRF activity lead to the prediction that 
CRFR antagonists may protect against excessive ethanol drinking, including binge-like drinking, 
in non-dependent animals because initial ethanol exposure augments CRF signaling (Lowery et 
al., 2009). 
Corticotropin-Releasing Factor and Ethanol Dependence 
 The current body of preclinical literature suggests that the role of CRF signaling in low or 
moderate ethanol intake in the early stages of ethanol drinking is limited.  For example, central 
administration of  non-selective CRFR antagonists, such as [D-Phe12,Nle21,38,CαMeLeu37]-
rCRF(12-41) (D-Phe-CRF) and α-helical CRF(9-41) (ahCRF), does not significantly alter ethanol 
consumption or self-administration in non-dependent rats or mice with a history of ethanol 
exposure akin to social drinking in humans (O'Callaghan, Croft et al. 2005; Funk, O'Dell et al. 
2006; Finn, Snelling et al. 2007).  Similar results have been obtained using peripheral 
administration of antagonists selective for the CRF1R, including (N,N-bis(2-methoxyethyl)-3-(4-
methoxy-2-methylpheenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-amine (MPZP) (Richardson, 
Zhao et al. 2008), 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-
imidazo[1,2-b]pyridazine (MTIP) (Gehlert, Cippitelli et al. 2007), (4-ethyl-[2,5,6-trimethyl-7-
(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino-1-butanol (LWH-63) (Sabino, 
Cottone et al. 2006), 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-
dipropylaminopyrazolo[1,5-a]pyrimidine (R121919, also called NBI 30775) (Sabino, Cottone et 
al. 2006), and [8-(4-bromo-2-chlorophenyl)-2,7-dimethyl-pyrazolo[1,5-a][1,3,5]triazin-4-yl]-bis-(2-
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methyoxyethyl)amine (MJL-1-109-2) (Sabino, Cottone et al. 2006). Though there are reports of 
a role for CRF in stress-induced ethanol consumption by non-dependent animals (Marinelli, 
Funk et al. 2007; Lowery, Sparrow et al. 2008), converging evidence indicates that CRFR 
signaling does not modulate low or moderate levels of ethanol consumption in non-dependent 
animals under non-stressed conditions. 
 Conversely, CRF signaling appears to be integral to ethanol consumption by animals in 
which ethanol dependence has been induced by repeated exposure to, and withdrawal from, 
ethanol vapor or an ethanol-containing diet. Following chronic exposure to ethanol by these 
methods, animals show characteristic phenotypes of ethanol dependence, including elevated 
ethanol consumption, enhanced anxiety-like behaviors, and increased stress responsivity, all of 
which can be attenuated by pretreatment with CRF1R antagonists (Heilig and Koob 2007; Koob 
2008; Lowery and Thiele 2009).  A converging body of literature indicates a pivotal role for 
CRF1R signaling in dependence-induced ethanol consumption, and recent studies have 
suggested a role for the CRF2R.  Central administration of the non-selective CRF antagonist D-
Phe-CRF into the ventricles attenuated dependence-induced increases in ethanol consumption 
in rats (Valdez, Roberts et al. 2002), as did peripheral administration of selective CRF1R 
antagonists, including antalarmin (Chu, Koob et al. 2007), MPZP (Gilpin, Richardson et al. 2008; 
Richardson, Zhao et al. 2008), LWH-63 (Sabino, Cottone et al. 2006), MJL-1-109-2 (Funk, 
Zorrilla et al. 2007), R121919 (Funk, Zorrilla et al. 2007), and MTIP (Funk, Zorrilla et al. 2007).  
Importantly, as noted above, manipulation of CRFR signaling with these antagonists did not 
alter ethanol drinking in non-dependent animals (i.e., animals that did not undergo dependence-
inducing procedures) that drank moderate amounts of ethanol. Further evidence indicates that 
the role of CRF1R signaling in dependence-induced increases in ethanol consumption is brain 
region-specific, as microinjections of D-Phe-CRF into the CeA, but not the BNST, attenuated 
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increased levels of ethanol consumption in ethanol-dependent rats to the levels of non-
dependent controls (Funk, O'Dell et al. 2006; Finn, Snelling et al. 2007).  Likewise, activation of 
the CRF2R by ventricular (Valdez, Sabino et al. 2004), or site-directed infusion into the CeA 
(Funk and Koob 2007) of Ucn3 also reduced ethanol consumption by ethanol-dependent rats. 
Additional evidence of a role for CRF in ethanol dependence comes from investigations of the 
msP rat, a line that was selectively bred for high ethanol intake. Even before exposure to 
ethanol, these animals resemble ethanol dependent animals in that they show behavioral 
indices of ethanol dependence and upregulations of CRF signaling (Ciccocioppo, Economidou 
et al. 2006). Recent investigations have revealed that the CRF1R antagonists MTIP (Gehlert, 
Cippitelli et al. 2007) and antalarmin (Hansson, Cippitelli et al. 2006) attenuated ethanol self-
administration in non-dependent msP rats, without effects in non-dependent outbred rats, 
suggesting that upregulations of the CRF system drive ethanol consumption. Together, these 
observations show the CRFR antagonists (and specifically those aimed at the CRF1R) and 
CRF2R agonists protect against dependence-induced increases in ethanol drinking. 
Furthermore, the CeA is a key brain region in which CRF1R blockade and CRF2R stimulation 
modulates dependence-induced ethanol intake. 
Corticotropin-Releasing Factor and Binge-Like Drinking 
An initial investigation from our lab suggests that CRF signaling modulates ethanol 
intake in non-dependent rodents when the level of ethanol intake is high. Using DID procedures 
to elicit binge-like ethanol consumption, results showed that pretreatment with the CRF1R 
antagonist butyl-ethyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7Hpyrrolo[2,3-d]pyrimidin-4-
yl]amine (CP-154,526) significantly attenuated binge-like drinking by C57BL/6J mice (which 
achieved BECs of greater than 80 mg/dL under control conditions). On the other hand, the 
CRF1R antagonist was ineffective in altering ethanol consumption in mice drinking moderate 
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amounts of ethanol and which achieved BECs of less than 40 mg/dL (Sparta, Sparrow et al. 
2008). These observations show that CRF1R signaling is necessary for excessive, but not for 
moderate, ethanol drinking, results which parallel observations showing that CRF1R antagonists 
exclusively attenuate dependence-induced ethanol consumption without effects on non-
dependent ethanol consumption. When considered together, these data strongly suggest that 
CRF is recruited during bouts of high ethanol drinking, in both models of dependence-like 
ethanol intake and non-dependent binge-like ethanol drinking. To date, the mechanisms by 
which CRF is initally recruited during excessive drinking by dependent animals and during 
binge-like drinking by non-dependent animals are unknown. Based on clinical data showing a 
link between binge drinking and ethanol dependence (Jennison 2004), an interesting possibility 
is that binge-like drinking is modulated by the same CRF neurocircuitry that underlies ethanol 
dependence. 
Goals of the Current Dissertation 
The goal of the current dissertation is to investigate the role of the central corticotropin-releasing 
factor (CRF) system, a neuropeptide system that is integral to ethanol dependence, in binge 
drinking that is not associated with ethanol dependence using the preclinical “drinking-in-the-
dark” model of binge-like ethanol consumption. The guiding hypothesis of the current 
dissertation is that binge-like drinking by non-dependent C57BL6/J mice recruits the 
extrahypothalamic CRF system, which is known to underlie behaviors associated with ethanol 
dependence, and that CRF signaling is necessary to maintain high levels of ethanol intake 
during an ethanol binge. The findings of this dissertation will provide further insight into the 
mechanisms that drive high levels of ethanol intake by non-dependent animals and will expand 
the current understanding of the role of CRF in ethanol intake that occurs before the onset of 
ethanol dependence. 
 CHAPTER 2 
THE EFFECTS OF CRF COMPOUNDS ON BINGE-LIKE ETHANOL CONSUMPTION BY 
C57BL/6J MICE 
 
 
Introduction 
 The corticotropin releasing factor (CRF) system modulates numerous behavioral and 
biological responses through two G-protein coupled receptors, the CRF1 receptor (CRF1R) 
and the CRF2 receptor (CRF2R) (Hauger, Risbrough et al. 2006).  Preclinical evidence 
suggests roles for both the CRF1R and the CRF2R in ethanol-related phenotypes, as non-
selective CRF receptor (CRFR) antagonists attenuate increased ethanol consumption 
stemming from ethanol dependence (Valdez, Roberts et al. 2002; Funk, O'Dell et al. 2006; 
Finn, Snelling et al. 2007).  Although growing evidence suggests a role for CRF2R in the 
modulation of ethanol consumption (Valdez, Sabino et al. 2004; Funk and Koob 2007; 
Sharpe and Phillips 2009; Lowery, Spanos et al. 2010), the CRF1R has been the primary 
focus of several pharmacological investigations.  Generally, the results of these 
investigations show that antagonism of the CRF1R by compounds such as antalarmin (Chu, 
Koob et al. 2007), LWH-63 (Sabino, Cottone et al. 2006), or R121919 (Funk, Zorrilla et al. 
2007) attenuate increased ethanol consumption associated with ethanol dependence.  
Interestingly, CRF antagonists do not alter ethanol consumption by animals that have not 
undergone procedures to induce ethanol dependence (i.e., chronic intermittent vapor 
exposure or chronic ethanol diet; seeLowery and Thiele 2009). Therefore, CRF does not 
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appear to modulate low to moderate levels of ethanol consumption by non-dependent 
animals under non-stressed conditions, leading to the hypothesis that CRF1R are 
selectively recruited under circumstances of high ethanol intake associated exclusively with 
dependence. 
Binge drinking is a common pattern of ethanol intake that yields pharmacologically 
relevant blood ethanol concentrations (i.e., 80 mg/dl or above) in a relatively short period of 
time (i.e., 2 hours) (Council 2004) and that may contribute to the development of ethanol 
dependence (Jennison 2004). Recent evidence indicates that the CRF system may 
modulate binge-like ethanol consumption by animals that have not undergone procedures to 
induce dependence (Sparta, Sparrow et al. 2008; Lowery, Spanos et al. 2010).  Specifically, 
an intraperitoneal (i.p.) injection of the CRF1R antagonist, CP-154,526, attenuated binge-
like ethanol consumption by male C57BL/6J mice that achieved BECs of 80 mg/dl or greater 
under control conditions (Sparta, Sparrow et al. 2008).  Interestingly, in the Sparta et al., 
(2008) report, CRF1R signaling appeared to be recruited by excessive levels of ethanol 
intake only, as pretreatment with CP-154,526 did not alter ethanol consumption by male 
C57BL/6J mice that drank moderate levels of ethanol with associated BECs of 40 mg/dl or 
less.  Together these data suggest that CRF signaling may modulate excessive binge-like 
ethanol consumption by non-dependent animals in addition to elevated ethanol consumption 
stemming from ethanol dependence.  These initial findings also suggest that the recruitment 
of the CRF system during even early bouts of ethanol intake may contribute to the 
development of ethanol dependence. 
To date, the role of the CRF system in binge-like ethanol consumption has been 
determined using only the peripherally bioavailable CRF1R anatagonist, CP-154,526.  The 
objective of the first aim of this dissertation was to extend these results by 1) verifying that 
these effects were centrally mediated and 2) by investigating the role of CRF2R in binge-like 
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ethanol consumption. As the findings of the Sparta et al. study suggested a novel role for 
the CRF system in binge-like ethanol consumption, an additional goal was to replicate the 
findings of this initial study. The current experiments assessed the effects of a centrally 
administered CRF antagonist (α-helical CRF9-41), three highly selective and peripherally 
bioavailable CRF1R antagonists (antalarmin, NBI27914 and LWH-63), and a CRF2R 
agonist (Ucn3) on binge-like ethanol consumption using DID procedures. The effects of the 
CRF1R antagonists on non-binge-like ethanol consumption were assessed using a protocol 
in which animals generally consume low amounts of ethanol and achieve low or moderate 
BECs. To verify the specificity of all compounds to binge-like ethanol consumption, the 
effects of each compound on binge-like sucrose consumption were assessed.  Here, we 
show that central administration of α-helical CRF9-41 or Ucn3 and peripheral administration of 
antalarmin (30 mg/kg), NBI27914 (30 mg/kg), or LWH-63 (30 or 60 mg/kg) significantly and 
selectively attenuated binge-like ethanol consumption by male C57BL/6J mice. Furthermore, 
administration of CRF1R antagonists did not alter low levels of ethanol consumption, and 
the lowest effective doses of each CRF compound did not alter consumption of a 10% 
sucrose solution.  These observations extend the current literature on the role of the CRF 
system in binge-like ethanol consumption, and provide further support for the hypothesis 
that the CRF system is recruited during bouts of high ethanol intake by non-dependent 
animals.    
 
Methods 
Animals 
Male C57BL/6J mice (Jackson Laboratories, Jackson MS) were 6-8 weeks of age and 
weighed 20-30 grams upon arrival.  Mice were housed individually in plastic cages and 
allowed to habituate to the environment for at least one week before experimental 
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procedures were initiated.  The animal colony room was maintained at approximately 22˚C 
with a 12h/12h light/dark cycle (lights off at 700 hours for experiments 2-5, 7b-e; lights off at 
1000 hours for experiments 1, 7a; lights off at 1900 hours for experiment 6).  Animals had 
ad lib access to food throughout all experiments, and free access to water except during 
ethanol access, as noted.  All procedures used are in accordance with the National Institute 
of Health guidelines, and were approved by the University of North Carolina Institutional 
Animal Care and Use Committee. 
 Drugs 
Ethanol (20% v/v) solutions were prepared using tap water and 95% ethyl alcohol (Decon 
Laboratories, King of Prussia PA), and sucrose (10% w/v) solutions were prepared using tap 
water and D-sucrose (Fisher Scientific, Fair Lawn NJ).  The non-selective CRF receptor 
antagonist, α-helical CRF9-41 (α-helical CRF; Sigma-Aldrich, Saint Louis, MO) was dissolved 
in sterile water and was injected intracerebroventricullarly (i.c.v.; vehicle, 1, 5, or 10 µg/ 1 µl) 
approximately 60 minutes prior to the start of behavioral testing.  Doses and the time course 
were based on previous studies (Brauns, Liepold et al. 2001; Nishikawa, Hata et al. 2004).  
This compound effectively blocks CRF-induced ACTH secretion in vitro and in vivo (Rivier, 
Rivier et al. 1984), and attenuates CRF-induced adenylate cyclase activity (Battaglia, 
Webster et al. 1987).  All CRF1R antagonists were dissolved in a 0.9% saline and emulphor 
(also known as Cremphor EL; Sigma-Aldrich, St. Louis MO) solution (10% emulphor v/v) 
and delivered intraperitoneally (i.p.) in a 10 ml/kg volume. The non-peptide selective CRF1R 
antagonist, NBI27914 (Tocris Biosciences, Ellisville MO) displays high affinity for the CRF1R 
(Ki= 1.7 nM) and effectively reduces CRF-induced ACTH secretion in rat anterior pituitary 
cell cultures, but does not alter cAMP production in CRF2α transfected cells (Chen, Dagnino 
Jr. et al. 1996).  This compound has been shown to attenuate anxiety-like behavior in 
arthritic rats when delivered peripherally (Ji, Fu et al. 2007).  Doses of 1, 5, 10, 20, 30, or 60 
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mg/kg were used here and were extrapolated from previous studies (Ji, Fu et al. 2007; Kim 
and Han 2009). We selected an expanded dose range because few studies to date have 
investigated the behavioral effects of this compound.  The non-peptide selective CRF1R 
antagonist, antalarmin (Sigma-Aldrich, St. Louis MO) displays high affinity for the CRF1R 
(Ki= 1.0 nM) vs. the CRF2R (Ki> 10000nM), (Valdez 2006) and has been shown to attenuate 
stress-induced ACTH release when administered peripherally (Deak, Nguyen et al. 1999).  
Additionally, antalarmin has been shown to attenuate ethanol consumption or self-
administration in ethanol-dependent rats or in rats exhibiting anxiety-like behavior (Lodge 
and Lawrence 2003; Chu, Koob et al. 2007; Funk, Zorrilla et al. 2007).  We selected the  30 
mg/kg dose based on previous research, and doses of above 30 mg/kg were not used to 
avoid non-specific effects which have been reported elsewhere (Chu, Koob et al. 2007). The 
non-peptidic selective CRF1R antagonist, (4-ethyl-[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-
7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino-1-butanol (LWH-63; Sigma-Aldrich, St. Louis MO), a 
structural analogue of antalarmin, displays high affinity for the CRF1R (Ki= 0.68) (Hsin, Tian 
et al. 2002).  LWH-63 has been shown to attenuate ethanol consumption in ethanol-
dependent phenotypes when delivered peripherally (Sabino, Cottone et al. 2006).  In the 
current study, the  10, 30, or 60 mg/kg doses were extrapolated from previous research 
(Sabino, Cottone et al. 2006).  The selective CRF2R agonist, Ucn3 (Phoenix 
Pharmaceuticals, Inc., Burlingame, CA) was dissolved in sterile water and was injected i.c.v. 
(vehicle, 0.05, 0.1, or 0.5 µg/ 1 µl) approximately 90 minutes prior to the start of behavioral 
testing.  Doses and the time course were extrapolated from previous research (Valdez and 
Koob 2004; Venihaki, Sakihara et al. 2004; D'Anna, Stevenson et al. 2005).  Ucn3 is a 
highly selective agonist for the CRF2R (Ki= 9.1 nM) versus the CRF1R (Ki> 10,000 nM) 
(Ryabinin, Bachtell et al. 2002; Hauger, Risbrough et al. 2006). 
“Drinking in the Dark” (DID) Procedure 
19 
 
A 4-day DID procedure was used in all experiments (Rhodes, Best et al. 2005; Sparta, 
Sparrow et al. 2008).  On days 1-3, beginning 2.5 h into the dark cycle, water bottles were 
removed from all cages.  For all experiments involving i.p. drug administration, animals were 
weighed and injected with the appropriate volume (10 ml/kg) of the specified vehicle to 
habituate them to injections.  For all experiments involving i.c.v. drug administration, animals 
were handled for 1 min per day on days 1-3 to habituate them with injection procedures.  
Beginning 3 h into the dark cycle, small ethanol bottles (or water bottles, where specified) 
were weighed (to the nearest 0.01 g) and placed on cages for 2 h (bottle were again 
weighed after removal to calculate consumption).  The same schedule was followed on day 
4, except that drug was administered prior to ethanol access and ethanol access was 
extended to 4 h and immediately thereafter, tail blood samples were collected for analysis of 
BECs. It should be noted that previous research has shown that giving water in tandem with 
ethanol during DID procedures does not alter the level of ethanol intake by mice. However, 
drinking water was shown to significantly attenuate BECs, likely the result of altered ethanol 
absorption (Rhodes et al., 2005). Thus, we chose to use the ethanol bottle only procedure 
here and in the following chapters. 
Surgery and Infusion Procedures 
Approximately 2 weeks after arrival, mice underwent surgery to implant cannulae aimed at 
the lateral ventricle.  Specifically, mice were anesthetized with a cocktail of ketamine (117 
mg/kg) and xylazine (7.92 mg/kg) and surgically implanted with a 26-gauge cannula (Plastic 
One, Roanok, VA) aimed at the left lateral ventricle (0.2 mm posterior to bregma, 1.0 mm 
lateral to the midline, and 2.3 mm ventral to the skull surface) (Navarro, Cubero et al. 2005).  
Mice were allowed to recover approximately 2 weeks before experimental procedures were 
started.  Cannula placement was verified histologically at the end of the experiment. The 
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i.c.v. infusions were given manually in a 1.0 µl volume over a 1-minute period with a 1.0 µl 
Hamilton microsyringe.  
Blood Ethanol Concentration 
Approximately 10 µl of blood was collected from the tail vein of each mouse immediately 
following ethanol access on day 4 of the DID procedure to analyze for blood ethanol 
concentration.  Samples were centrifuged, and 5 µl of plasma from each sample was 
analyzed (Analox Instruments, Lunenburg, MA). 
Experiment 1: The effects of a CRFR antagonist on binge-like ethanol drinking 
Animals were assigned to groups equated for ethanol consumption during the first three 
days of DID procedures. On day 4, groups were given an i.c.v. infusion of 1, 5, or 10 µg/ 1 µl 
of α-helical CRF or equal volume of vehicle prior to ethanol access as described above. 
Immediately following 4-h ethanol access on day 4, approximately 10 µl of blood were 
collected from the tail vein of each animal. 
Experiments 2-4: The effects of CRF1R antagonists on binge-like ethanol drinking 
Groups were formed based on equated ethanol consumption during days 1-3.  On day 4, 
beginning 2.5 h into the dark cycle animals were weighed and injected with the appropriate 
volume of CRF1R antagonist or vehicle.  In Experiment 2, animals were pretreated with 30 
mg/kg of antalarmin or vehicle prior to ethanol access. In Experiment 3, mice were 
pretreated with 1, 5, or 10 mg/kg NBI27914 or vehicle.  Since none of these doses had 
effects on ethanol consumption, a second round of DID was used to test additional doses.  
Animals were re-distributed to groups and pretreated with the appropriate dose of NBI27914 
(10, 20, or 30 mg/kg) or vehicle.  A third round of DID was used to further expand the dose 
range, in which mice received i.p. injection of 10, 30, or 60 mg/kg of NBI27914 or vehicle.  
Each exposure was separated by at least 3 days, during which animals did not have access 
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to ethanol. In Experiment 4, animals were pretreated with 10, 30, or 60 mg/kg of LWH-63 or 
vehicle prior to ethanol access on day 4. Immediately following 4-h ethanol access on day 4, 
approximately 10 µl of blood were collected from the tail vein of each animal. 
Experiment 5: The effects of a CRF2R agonist on binge-like ethanol drinking 
Animals were assigned to groups equated for ethanol consumption during the first three 
days of DID procedures. On day 4 mice were given i.c.v. infusions of 0.05, 0.1, or 0.5 µg/ 1 
µl of Ucn3 or equal volume of vehicle prior to ethanol access as described above. 
Immediately following 4-h ethanol access on day 4, approximately 10 µl of blood were 
collected from the tail vein of each animal. 
Experiment 6: The effects of CRF1R antagonists on non-binge-like ethanol drinking 
Experiment 6 used a 4-day procedure called “drinking-in-the-light” (DIL) to assess the 
effects of CRF1R antagonists on moderate levels of ethanol consumption. On day 1, 
beginning 2.5 h into the light cycle, animals were weighed and injected with the appropriate 
volume of vehicle to habituate them with the injection procedure.  At 3 h into the light cycle, 
water bottles were removed from all cages and replaced with bottles containing a 20% 
ethanol solution.  Animals had 2-h of access to ethanol, after which ethanol bottles were 
removed from cages and water bottles were replaced.  The same procedure was followed 
on days 2 and 3, except that animals were not weighed and injection volumes were based 
on body weights from day 1.  Groups were formed based on equated ethanol consumption 
during days 1-3.  On day 4, beginning 2.5 h into the light cycle, animals were weighed and 
injected with the appropriate volume of CRF1R antagonist (30 mg/kg of antalarmin, 30 
mg/kg of NBI27914, or 30 mg/kg of LWH-63) or vehicle.  At 3 h into the light cycle, water 
bottles were removed from all cages and replaced with bottles containing a 20% ethanol 
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solution for 4 h.  Blood samples from the tail vein of each animal were collected and 
analyzed for BECs as described above. 
Experiment 7: The effects of CRF compounds on consumption of a 10% sucrose solution 
An additional set of ethanol naïve mice were used to assess the effects of the effective 
doses of each CRF compound on consumption of a 10% sucrose solution, a concentration 
which has been used previously to assess the specificity of drug effects to ethanol 
consumption (Sparta, Sparrow et al. 2008). All procedures were identical to those described 
above, except that 10% sucrose solution was given in place of 20% ethanol.  Animals were 
divided into groups equated for consumption of sucrose solution on days 1-3.  On day 4, 
animals were pretreated with doses of compounds that reduced ethanol consumption (1 µg/ 
1 µl α-helical CRF; 30 or 60 mg/kg NBI27914, 30 or 60 mg/kg LWH-63, or 30 mg/kg 
antalarmin, 0.1 or 0.5 µg/ 1 µl Ucn3) or vehicle . 
Data Analysis 
Differences in ethanol consumption between the first three days of each DID experiment 
were assessed using a one-way repeated-measures analyses of variance (ANOVA) to 
confirm that drug treatment groups did not significantly differ from one another prior to drug 
administration.  The main effect of drug treatment on ethanol consumption and associated 
BECs on day 4 of each DID experiment were assessed using one-way ANOVAs, and LSD 
post-hoc tests were used to assess specific differences between drug groups and the 
vehicle group where appropriate. Identical analyses were used to assess the effects of CRF 
compounds on consumption of a sucrose solution or non-binge-like ethanol consumption.  
Significance was accepted at the P < 0.05 (two-tailed).  All data are presented as mean ± 
SEM. 
Results 
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Experiment 1: The effects of α-helical CRF on binge-like ethanol drinking 
Ethanol consumption during the first three days of DID for all experiments is shown in Table 
2.1. The results of a repeated measures ANOVA confirmed that drug treatment groups did 
not differ in ethanol consumption during the first three days of DID (F(3, 30)= 1.06, p = 0.380).  
As shown in Figure 2.1A, ethanol consumption on the fourth day of the DID procedure was 
significantly affected by drug treatment (F(3, 31)= 3.183, p = 0.039), as were blood ethanol 
concentrations (F(3, 31)= 3.792, p = 0.021; see Figure 2.1B). Post-hoc analyses revealed that 
animals pretreated with 1 µg of α-helical CRF consumed significantly less ethanol than 
animals pretreated with vehicle. Animals pretreated with 1, 5 or 10 µg of α-helical CRF 
achieved significantly lower BECs than animals pretreated with vehicle.  
Experiment 2: The effects of antalarmin on binge-like ethanol consumption 
The results of a repeated measures ANOVA confirmed that drug treatment groups did not 
differ in ethanol consumption during the first three days of DID (F(1, 22) = 0.25, p = 0.875). An 
ANOVA revealed a significant effect of drug treatment on day 4 (F(1, 25) = 6.548, p = 0.017), 
confirming that the 30 mg/kg dose of antalarmin significantly blunted binge-like ethanol 
drinking (Figure 2.2A).  Similar significant effects were also observed for BECs (F(1,25)= 
4.296, p = 0.049), as pretreatment with antalarmin significantly reduced BECs (Figure 2.2B). 
Experiment 3: The effects of NBI27914 on binge-like ethanol consumption 
The results of a repeated measures ANOVA confirmed that drug treatment groups did not 
differ in ethanol consumption during the first three days of any DID cycle (Cycle 1: F(3, 35)= 
0.091, p = 0.964; Cycle 2: F(3, 36)= 0.054, p = 0.983; Cycle 3: F(3, 36)= 0.013, p = 0.998). As 
shown in Figure 2.3A, pretreatment with 1, 5, or 10 mg/kg of NBI27914 did not significantly 
alter binge-like ethanol consumption on day 4 of the first round of DID (F(3, 39)= 2.159, p = 
0.110), and likewise BECs did not significantly differ between groups (F(3, 39) = 0.826, p = 
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0.488; see Figure 3D).  An ANOVA performed on ethanol consumption data from the 
second round of DID was significant (F(3, 30)= 5.833, p = 0.002).  Post-hoc tests revealed that 
pretreatment with the 30 mg/kg dose of NBI27914 significantly attenuated binge-like ethanol 
consumption relative to vehicle treatment (Figure 2.3B).  However, an ANOVA performed on 
BEC data from the second round of DID was not significant (F(3, 39)= 1.848, p = 0.156; see 
Figure 2.3E).  On the third round of DID, the effect of drug treatment on binge-like ethanol 
consumption data was statistically significant (F(3, 37)= 18.512, p < 0.001).  Post-hoc analyses 
reveal that pretreatment with 30 or 60, but not 10, mg/kg doses of NBI27914 significantly 
attenuated binge-like ethanol consumption relative to vehicle (Figure 2.3C).  Likewise, an 
ANOVA performed on BEC data from the third round of DID was significant (F(3, 37)= 8.048, p 
< 0.001), and post-hoc analyses indicate that pretreatment with 60 mg/kg resulted in 
significantly reduced BECs relative to vehicle (Figure 2.3F). 
Experiment 4: The effects of LWH-63 on binge-like ethanol consumption 
The results of a repeated measures ANOVA confirmed that drug treatment groups did not 
differ in ethanol consumption during the first three days of DID (See Table 2.1), (F(3, 36)= 
0.057, p = 0.982). An ANOVA revealed a significant effect of drug treatment on binge-like 
ethanol consumption data (F(3, 39)= 13.591, p < 0.001), and post-hoc analyses show that 
pretreatment with both 30 and 60 mg/kg doses of LWH-63 significantly attenuated binge-like 
ethanol consumption relative to vehicle treatment (Figure 2.4A).  Similarly, an ANOVA 
performed on associated BECs was statistically significant (F(3, 39)= 9.402, p < 0.001), and 
post-hoc analyses indicate that pretreatment with both the 30 and 60 mg/kg doses 
significantly reduced BECs (see Figure 2.4B). 
Experiment 5: The effects of Ucn3 on binge-like ethanol drinking 
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The results of a repeated measures ANOVA confirmed that drug treatment groups did not 
differ in ethanol consumption during the first three days of DID (F(3, 31)= 0.230, p = 0.874).  
As shown in Figure 2.5A, ethanol consumption on the fourth day of the DID procedure was 
dose-dependently affected by drug treatment (F(3, 32)= 6.010, p = 0.003), as were blood 
ethanol concentrations (F(3, 29)= 6.504, p = 0.002; see Figure 5B).  Post-hoc analyses 
revealed that animals pretreated with 0.05, 0.1 or 0.5 µg of Ucn3 consumed significantly 
less ethanol and achieved significantly lower BECs than animals pretreated with vehicle. 
Experiment 6: The effects of CRF1R antagonists on non-binge-like ethanol drinking 
The results of a repeated measures ANOVA confirmed that drug treatment groups did not 
differ in ethanol consumption during the first three days of DID (F(3, 31)= 0.238, p = 0.869). An 
ANOVA showed that drug treatment did not significantly alter ethanol consumption (F(3, 34)= 
1.068, p = 0.377; see Figure 2.6A).  An ANOVA performed on associated BECs was 
statistically significant (F(3, 34)= 3.190, p = 0.037), and post-hoc analyses indicate that 
pretreatment with the 30 mg/kg dose of LWH-63 significantly increased BECs (see Figure 
2.6B). 
Experiment 7: The effects of CRF compounds on consumption of a 10% sucrose solution 
Consumption of a 10% sucrose solution was not altered by pretreatment with 1 µg of α-
helical CRF, as confirmed by the results of a one-way ANOVA (F(1, 19)= 2.749, p = 0.115; see 
Figure 2.7A). A one-way ANOVA showed that sucrose consumption was not altered by 
pretreatment with 30 mg/kg of antalarmin (F(1, 19)= 0.70, p = 0.795; see Figure 2.7B). For the 
NBI27914 and LWH-63 control study, the results of a one-way ANOVA reveal a significant 
main effect of drug treatment on consumption of a 10% sucrose solution, (F(4, 49)= 8.560, p < 
0.001), and post-hoc analyses reveal that pretreatment with the 60 mg/kg dose of NBI27914 
significantly reduced sucrose consumption relative to vehicle treatment (Figure 2.7C). 
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Consumption of a 10% sucrose solution was not altered by pretreatment with either 0.1 µg 
or 0.5 µg Ucn3, as confirmed by the results of a one-way ANOVA (F(2, 27)= 0.101, p = 0.904; 
see Figure 2.7D). 
Discussion 
 The results of the current study provide strong evidence in support of a role for the 
CRF system in binge-like ethanol consumption by non-dependent animals. These effects 
appear to be specific for binge-like ethanol consumption (as opposed to non-binge-like 
ethanol consumption), are likely centrally mediated, and may involve both the CRF1R and 
the CRF2R. First, central pretreatment with a CRF1/2R antagonist (α-helical CRF) or a 
CRF2R agonist (Ucn3) attenuated binge-like ethanol consumption by non-dependent 
C57BL/6J mice. Similar results were observed following systemic pretreatment with each of 
three peripherally bioavailable CRF1R antagonists. These effects were specific for binge-
like ethanol consumption, as the lowest effective dose of each compound did not alter 
consumption of a sucrose solution. Furthermore, pretreatment with each of three CRF1R 
antagonists did not alter ethanol consumption that was associated with BECs of 50 mg/dl or 
lower, thus suggesting that CRF1R are not involved in non-binge-like ethanol consumption 
by non-dependent animals. 
The results of the current study provide further support for emerging data indicating a 
role for CRF1R in binge-like ethanol consumption using DID procedures (Sparta, Sparrow et 
al. 2008; Lowery, Spanos et al. 2010; Kaur, Li et al. 2011).  In agreement with our findings 
using antalarmin, NBI27914, and LWH-63, previous studies have reported attenuation of 
binge-like ethanol consumption following systemic injections of the CRF1R antagonist, CP-
154,526, a structural analogue of antalarmin (Sparta, Sparrow et al. 2008; Lowery, Spanos 
et al. 2010).  Thus, compounds displaying high selectivity for the CRF1R reduce the amount 
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of ethanol consumed during a would-be binge-like drinking episode. In agreement with these 
pharmacological investigations, a recent report demonstrated that CRF1R knockout mice 
consume significantly less ethanol and achieve significantly lower BECs than wildtype mice 
under DID conditions (Kaur, Li et al. 2011). Considering these results in tandem with 
additional data indicating that central infusions of the non-selective CRFR antagonist, alpha-
helical CRF9-41 also attenuated binge-like ethanol consumption (Lowery, Spanos et al. 2010), 
it is reasonable to hypothesize that central CRF1R signaling is recruited during bouts of 
excessive binge-like ethanol consumption, as defined by BECs in excess of 80 mg/dl.  It is 
important to note that pretreatment with another non-peptide, small molecule CRF1R 
antagonist, MPZP, failed to attenuate binge-like consumption of a sweetened ethanol 
solution by rats (Ji, Gilpin et al. 2008).  However, these divergent results may be due to 
several procedural differences between the current experiment and the experiment by Ji and 
colleagues, including species used (mouse vs. rat), and ethanol solution used (unsweetened 
vs. sweetened), among other factors. 
A well-established body of research strongly implicates the CRF1R in ethanol intake 
associated with a history of ethanol dependence, as CRF1R antagonists prevent relapse to 
ethanol-seeking behavior or ethanol consumption by animals that have undergone 
procedures to induce dependence.  In contrast, results of parallel experiments suggest that 
CRF1R antagonists do not affect these behaviors in animals that have not undergone 
dependence-inducing procedures, and thus are not ethanol dependent (see Lowery and 
Thiele 2009 for review).  However, an emerging literature demonstrates that the CRF1R can 
be recruited by ethanol intake in non-dependent animals when levels of ethanol 
consumption are high.  Indeed, CRF1R antagonists have been previously shown to block 
the heightened ethanol consumption associated with the alcohol deprivation effect (ADE) 
(Sparta, Ferraro et al. 2009), as well as attenuate binge-like ethanol consumption using DID 
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procedures.  In accordance with previous reports, the current results illustrate this point, as 
the CRF1R antagonists tested here (and CP-154,526 tested previously; see Sparta et al., 
2008) did not alter moderate levels of ethanol intake (associated with BECs below 50 mg/dl) 
at doses which effectively attenuated binge-like ethanol consumption (associated with BECs 
in excess of 80 mg/dl).  Thus, it appears that some threshold of BECs must be crossed 
before the CRF system is recruited during a period of ethanol consumption.  Alterations in 
neurobiology support this hypothesis, as increased expression of CRF system markers (i.e., 
immunoreactivity, heteronuclear RNA, messenger RNA) in extrahypothalamic brain regions 
is observed in animals with a history of ethanol dependence, but no changes are seen in 
these areas in animals that are non-dependent (see Lowery and Thiele 2009 for review).  
Considering these observations and the current results, it is tempting to speculate that 
activation of the CRF system occurs when a threshold of BECs is crossed due to high levels 
of intake, regardless of ethanol history, and that CRF1R antagonists protect against 
pathological drinking behaviors (i.e., dependence-induced, deprivation-induced and binge-
like ethanol consumption) by blocking receptors in brain regions that modulate these 
behaviors.  Though there is indirect evidence in support of this hypothesis (the current 
results and (Lowery, Spanos et al. 2010)), this remains an important experimental question.   
Another interesting possibility is that alterations in the CRF system that are 
considered a hallmark characteristic of dependent animals are developed through repeated 
exposures to high ethanol drinking, as observed during binge-like ethanol drinking, but not 
through repeated exposures to moderate ethanol drinking. Thus, CRF1R antagonists are 
only efficacious in attenuating high levels of ethanol consumption, but not moderate levels of 
ethanol consumption, as observed in the current study.  Indeed, emerging clinical evidence 
has linked habitual binge drinking behavior to later alcohol dependence (Bonomo, Bowes et 
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al. 2004; Jennison 2004; Keyes, Grant et al. 2008), a transition which may be reflected 
neurobiologically by progressive changes in the CRF system (Koob 2003).  
It is important to note that the CRF1Rs can be activated by binding with either of two 
endogenous ligands, CRF and Ucn1, which have distinct patterns of expression in the brain 
(Hauger, Risbrough et al. 2006).  Both CRF and Ucn1 have been implicated in ethanol-
related behaviors, with reports directly demonstrating the involvement of the CRFRs (and 
primarily the CRF1R) in ethanol consumption associated with dependence or stress and 
Urocortin I’s involvement in limited access ethanol consumption (Ryabinin, Yoneyama et al. 
2008).  With respect to binge-like ethanol consumption, a recent report suggests that 
CRF1R signaling due to CRF binding, and not Ucn1, is critical as both CRF1R knockout 
mice and CRF knockout mice, but not Ucn1 knockout mice, showed attenuated binge-like 
ethanol consumption and BECs relative to wildtype controls (Kaur, Li et al. 2011).   
An unexpected observation of the current report was that central infusion of the non-
selective CRFR antagonist α-helical CRF
 
did not attenuate ethanol consumption in a dose-
dependent manner. This finding is in agreement with a previous observation of a biphasic 
effects of α-helical CRF
 
on reinstatement to heroin-seeking behavior, where lower doses 
(e.g., 3 µg) attenuated reinstatement and higher doses (e.g., 10 µg) had no effect on 
behavior (Shaham, Funk et al. 1997).  Similar biphasic effects of this drug have also been 
noted for anxiety-like behavior induced by ethanol withdrawal (Rassnick, Heinrichs et al. 
1993; Menzaghi, Rassnick et al. 1994) or stress (Heinrichs, Menzaghi et al. 1994). Such 
biphasic effects of α-helical CRF on behavior may be due in part to this drug’s actions as a 
partial agonist at the CRF1R with increasing doses (Smart, Coppell et al. 1999). As central 
administration of CRF promotes hyperactivity and stereotyped behavior (Veldhuis and De 
Wied 1984; Matsuzaki, Takamatsu et al. 1989; Song, Earley et al. 1995; Song, Earley et al. 
1997; Terawaki, Koike et al. 2004), it is possible that hyperactivity in mice that received the 
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10 µg dose of α-helical CRF caused ethanol spillage, which would account for low BECs in 
this group despite what appeared to be high levels of ethanol intake. 
Here we provide novel evidence that central CRF2R signaling also modulates binge-
like ethanol drinking, as central infusion of the highly selective CRF2R agonist Ucn3 
attenuated binge-like ethanol consumption in C57BL/6J mice. Recent evidence suggests 
that the CRF2R may modulate moderate ethanol consumption as well (Sharpe and Phillips 
2009). Therefore, the remainder of this dissertation will focus on the role of CRF and the 
CRF1R in binge-like ethanol consumption. The next chapter will explore brain regions in 
which CRF may be modulating binge-like ethanol consumption using immunohistochemistry 
procedures. 
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Table 2.1. Mean ethanol consumption (g/kg/2h ± SEM) on days 1-3 of DID procedures 
Experiment Drug Day 1 Day 2 Day 3 
 
1 
 
 
α-helical CRF 
 
2.42 ± 0.18 
 
4.02 ± 0.19 
 
3.52 ± 0.21 
2 
 
Antalarmin 2.03 ± 0.16 2.23 ± 0.17 2.23 ± 0.17 
3 
 
NBI27914 3.17 ± 0.12 2.92 ± 0.18 3.43 ± 0.17 
 
 
 3.06 ± 0.20 3.39 ± 0.16 3.78 ± 0.16 
 
 
 2.78 ± 0.14 3.33 ± 0.11 3.72 ± 0.15 
4 
 
LWH-63 2.65 ± 0.15 2.74 ± 0.15 2.80 ± 0.25 
5 
 
Ucn3 2.65 ± 0.14  3.11 ± 0.17 3.88 ± 0.19 
6 Antalarmin, 
NBI27614, LWH-63 
1.01 ± 0.14 0.87 ± 0.15 1.02 ± 0.17 
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Figure 2.1. Effects of the CRF1/CRF2 receptor antagonist α-helical CRF on mean binge-like 
ethanol consumption (A) and mean BECs (B). Values shown are mean ± SEM; n= 5-10 per 
group. * denotes significant difference from the vehicle group (p < 0.05). 
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Figure 2.2. Effects of the CRF1R antagonist antalarmin on mean binge-like ethanol 
consumption (A) and mean BECs (B). Values shown are mean ± SEM; n= 13 per group. * 
denotes significant difference from the vehicle group (p < 0.05). 
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Figure 2.3. Effects of the CRF1R antagonist NBI27914 on mean binge-like ethanol 
consumption (A-C) and mean BECs (B). Values shown are mean ± SEM; n= 10 per group. * 
denotes significant difference from the vehicle group (p < 0.05). 
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Figure 2.4. Effects of the CRF1R antagonist LWH-63 on mean binge-like ethanol 
consumption (A) and mean BECs (B). Values shown are mean ± SEM; n= 10 per group. * 
denotes significant difference from the vehicle group (p < 0.05). 
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Figure 2.5. Effects of the CRF2R agonist Ucn3 on mean binge-like ethanol consumption (A) 
and mean BECs (B). Values shown are mean ± SEM; n= 6-8 per group. * denotes 
significant difference from the vehicle group (p < 0.05). 
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Figure 2.6. Effects of the CRF1R antagonists on mean non-binge-like ethanol consumption 
(A) and mean BECs (B). Values shown are mean ± SEM; n= 8-9 per group. * denotes 
significant difference from the vehicle group (p < 0.05). 
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Figure 2.7. Effects of α-helical CRF (A), antalarmin (B), NBI27914 and LWH-63 (C) and 
Ucn3 (D) on mean sucrose consumption. Values shown are mean ± SEM; n= 10 per group. 
* denotes significant difference from the vehicle group (p < 0.05). 
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 CHAPTER 3 
THE EFFECTS OF BINGE-LIKE ETHANOL CONSUMPTION ON DEPENDENCE-LIKE 
BEHAVIORS AND THE EXPRESSION OF CRF IMMUNOREACTIVITY 
 
 
Introduction 
 
Alcoholism is a chronic and progressive disorder characterized by cyclic patterns of 
excessive ethanol self-administration intermixed with periods of withdrawal and abstinence, 
followed by relapse (Koob 2003; Breese, Chu et al. 2005).  As such, alcoholism can be 
conceptualized in terms of shifts in allostatic load, wherein repeated exposure and 
withdrawal from alcohol promote gradual neurobiological alterations within the brain which 
translate into psychological and behavioral changes leading to excessive uncontrolled 
ethanol consumption (Koob 2003). One such neurobiological system that exhibits 
progressive plastic changes over the course of ethanol exposure is the CRF system, as the 
effects of ethanol observed during acute and/ or early stages of exposure are distinct from 
those that are observed during the late stages of exposure and during dependence (Koob 
2003; Heilig and Koob 2007; Koob and Kreek 2007; Koob 2008; Lowery and Thiele 2009).   
Specifically, numerous studies have shown that acute ethanol administration 
increases CRF markers, including CRF-like immunoreactivity (CRF-IR), primarily within the 
hypothalamus   (Redei, Branch et al. 1988; Rivier and Lee 1996; Lee, Selvage et al. 2004; 
Li, Kang et al. 2005). In contrast, following extended exposure to ethanol and/ or induction of 
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ethanol dependence, upregulation of CRF markers is observed in regions of the extended 
amygdala, including the amygdala (Pich, Lorang et al. 1995; Lack, Floyd et al. 2005; Funk, 
O'Dell et al. 2006; Sommer, Rimondini et al. 2008), bed nucleus of the stria terminalis 
(BNST; Olive, Koenig et al. 2002), and the hypothalamus (Rivier, Imaki et al. 1990; Oliva 
2007). Long-term investigations show that some of these neurobiological changes in CRFR 
signaling persist months into abstinence, which may contribute to the enhanced anxiety-like 
behaviors and stress responsiveness that are observed long after ethanol administration 
has ceased (Valdez, Roberts et al. 2002; Valdez, Zorrilla et al. 2003; Breese, Chu et al. 
2005; Zhang, Morse et al. 2007; Falco, Bergstrom et al. 2009).  Interestingly, follow-up 
investigations show that some of these changes can be normalized through reinstatement of 
ethanol self-administration (Olive, Koenig et al. 2002). These observations are consistent 
with the hypothesis that a dysregulation of CRF signaling emerges over the transition to 
ethanol dependence, and that this dysregulation may contribute to the excessive and 
uncontrolled ethanol intake and increased display of anxiety-like behaviors that are 
indicative of the emergence of ethanol dependence (Koob 2003; Heilig and Koob 2007; 
Koob 2009).  
As binge drinking is known to increase the risk of developing ethanol dependence 
(Bonomo, Bowes et al. 2004; Jennison 2004), it is possible that the dysregulation of CRF 
signaling observed during ethanol dependence develops and progresses over the course of 
repeated bouts of binge drinking. To test this hypothesis, we assessed the effects of one or 
six cycles of binge-like ethanol consumption on the expression of CRF throughout the brain 
using DID procedures and immunohistochemistry. We also assessed the effects of one or 
six cycles of binge-like ethanol consumption on subsequent voluntary ethanol consumption 
and anxiety-like behaviors to ascertain if one or six cycles of DID induces behaviors that are 
consistent with a dependence-like state.  Here, we show that six cycles, but not one cycle, 
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of binge-like ethanol consumption led to a significant increase of 24-hour voluntary ethanol 
consumption and that neither one nor six cycles of binge-like ethanol consumption altered 
anxiety-like behaviors in elevated plus maze (EPM) and open-field activity tests. These 
findings suggest that multiple cycles of binge-like ethanol consumption promoted increased 
voluntary ethanol consumption, consistent with models of dependence-like drinking, but 
failed to alter anxiety-like behaviors (inconsistent with models of dependence-like drinking)t. 
Additionally, we observed significant elevations of CRF-IR in the central nucleus of the 
amygdala (CeA) following one and six cycles of binge-like ethanol consumption and in the 
ventral tegmental area (VTA) following one cycle of binge-like ethanol consumption. 
Together, these observations suggest that binge-like ethanol consumption by non-
dependent animals recruits the CRF system of the CeA and the VTA, brain regions that are 
integral to ethanol dependence and reward, respectively. 
 
Methods 
Animals 
Male C57BL/6J mice (Jackson Laboratories, Jackson MS) were 6-8 weeks of age and 
weighed 20-30 grams upon arrival.  Mice were housed individually in plastic cages and 
allowed to habituate to the environment for at least one week before experimental 
procedures were initiated.  The animal colony room was maintained at approximately 22˚C 
with a 12h/12h light/dark cycle (lights off at 700 hours).  Animals had ad lib access to food 
throughout the experiment, and free access to water except during ethanol access, as 
noted.  All procedures used are in accordance with the National Institute of Health 
guidelines, and were approved by the University of North Carolina Institutional Animal Care 
and Use Committee. 
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 Drugs 
Ethanol (20% v/v) solutions were prepared using tap water and 95% ethyl alcohol (Decon 
Laboratories, King of Prussia PA), and sucrose (10% w/v) solutions were prepared using tap 
water and D-sucrose (Fisher Scientific, Fair Lawn NJ).     
‘Drinking in the Dark’ (DID) Procedures 
All experiments used the 4-day DID procedure (Rhodes, Best et al. 2005; Rhodes, Ford et 
al. 2007; Sparta, Sparrow et al. 2008; Lowery, Spanos et al. 2010).  Specifically, on days 1-
3, beginning 3 h into the dark cycle, water bottles were removed from cages and replaced 
with bottles containing 20% ethanol solution.  Animals had 2-h of access to ethanol, after 
which ethanol bottles were removed from cages and water bottles were replaced.  The 
same procedure was followed on day 4, except that ethanol access was extended to 4 h. 
Different groups of mice experienced one 4-day binge-like drinking cycle while a second 
group experienced 4-day binge-like drinking cycles (with 3 days of rest between cycles). A 
third group drank water throughout the experiment. 
Assessment of Blood Ethanol Concentrations (BECs) 
Immediately following the 4-h ethanol access, approximately 10 µl of blood from the tail vein 
of each animal was collected.  Blood samples were centrifuged, and 5 µl of plasma were 
analyzed for BECs using the Analox Alcohol Analyzer (Analox Instruments, Lunenburg MA). 
Perfusions, Brain Preparation, and Immunohistochemistry (IHC) 
Immunohistochemistry procedures were based on those routinely used in our laboratory 
(Hayes, Knapp et al. 2005). Within one hour of ethanol access on the 4th day of the final DID 
exposure, mice were perfused transcardially with 0.1 mM phosphate-buffered saline (PBS; 
pH7.4) followed by 4% paraformaldehyde in phosphate buffer.  The brains were collected 
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and post-fixed in paraformaldehyde for 48 hours at 4°C, at which point they were transferred 
to PBS. The brains were cut using a vibratome into 40 µm sections that were then stored in 
cryopreserve until the IHC assay. Sections were then transferred to PBS for 24 h before 
processing with CRF antibody. After rinsing in fresh PBS 4 times (10 minutes each), tissue 
sections were blocked in 10% goat serum and 0.1% triton-X-100 in PBS for 1 hour. Sections 
were then transferred to fresh PBS containing primary antibody for 72 h at 5°C.  CRF 
expression was detected using primary rabbit anti-CRF (Peninsula Laboratories, LLC, San 
Carlos, CA; 1:5000 as determined by pilot studies).  As a control to determine if staining 
required the presence of the primary antibodies, some sections were run through the assay 
without primary antibody. In each assay described below, tissue processed without the 
primary antibody failed to show staining that was evident in tissue processed with primary 
antibody. After the 72 h of incubation, the sections were rinsed 4 times and then processed 
with Vectastain Elite kits (Vector Labs) as per the manufacturer’s instructions for standard 
ABC/HRP/diaminobenzidine-based immunohistochemistry. The sections processed for CRF 
were visualized by reacting the sections with a 3,3′-diamino-benzidine tetrahydrochloride 
(DAB; Polysciences, Inc., Warrington, PA) reaction solution containing 0.05% DAB, 0.005% 
cobalt, 0.007% nickel ammonium sulfate, and 0.006% hydrogen peroxide. All sections were 
mounted on glass slides, air-dried overnight, and cover slipped for viewing. Digital images of 
CRF immunohistochemistry (CRF-IR) and Ucn immunohistochemistry were obtained on a 
Nikon E400 microscope equipped with a Nikon Digital Sight DS-U1 digital camera run with 
Nikon-provided software.  Densitometric procedures were used to assess levels of CRF-IR 
and Ucn-IR in predetermined brain regions of interest where staining was visible.  Flat-field 
corrected digital pictures (8-bit grayscale) were taken using the Digital Sight DS-U1 camera.  
For the CRF-IR in all brain regions of interests, the density of staining was analyzed using 
Image J software (Image J, National Institute of Health, Bethesda, MD) by calculating the 
percent of the total area examined that showed signal (cell bodies and processes) relative to 
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a subthreshold background.  The size of the areas that were analyzed were the same 
between animals and groups. The subthreshold level for the images was set in such a way 
that any area without an experimenter-defined level of staining was given a value of zero. 
Anatomically matched pictures of the left and right sides of the brain were used to produce 
an average density for each brain region from each slice. In all cases, quantification of 
immunohistochemistry data was conducted by an experimenter that was blinded to group 
identity.  For analysis, great care was taken to match sections through the same region of 
brain and at the same level using anatomic landmarks with the aid of a mouse stereotaxic 
atlas (Paxinos and Franklin 2004).   
Experiment 1: The effects of binge-like ethanol drinking on anxiety-like behaviors and 
voluntary two-bottle choice ethanol consumption 
Each animal was assigned to one of the following groups upon arrival: water, 1-cycle, or 6-
cycles of binge-like drinking.  Animals of the water group had access to water only for the 
duration of the experiment.   Twenty-four hours after the final exposure to ethanol, anxiety-
like behavior was first assessed using a 5-min test on the elevated plus maze followed by a 
10-min test in an open field chamber. The EPM (MED Associates, Inc.) was positioned in 
the center of the room directly below a ceiling-mounted lamp fitted with a single 25-watt red 
light bulb which provided the only light for the room. Each mouse was placed onto the center 
square of the EPM with its nose pointing towards one of the open arms. The test session 
was video recorded with a tripod-mounted camcorder. Sessions were scored by blind 
investigators for time spent (min), and the proportion of total time spent, in the open arm 
defined as open arm time divided by total time spent in both arms. An animal was 
considered to have entered an arm of the plus maze if all four paws had left the center 
square. Open and closed arm time was considered terminated once a single paw was 
placed back into the center square. Approximately 5-10 min following the EPM test, each 
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animal was placed individually in an open field chamber that automatically recorded activity 
via photo beam breaks (Harvard Apparatus, Inc.). The open field arena measured 40.64 × 
40.64 × 30.48 cm and was made of clear Plexiglass. Several cms of corncob bedding were 
placed into the open field chamber to aid in cleaning and to prevent the buildup of odor. 
Horizontal distance traveled (in cm2) in the margin as compared to the center of the open 
field was recorded as an index of anxiety-like behavior, as anxious animals tend to spend 
more time near the margins of the arena.  For one week following the final 4-day DID cycle, 
all animals underwent a period of ethanol abstinence in which they had free access to water, 
but did not receive access to ethanol. Following this period of abstinence, all animals were 
given 24-h access two bottles, one containing ethanol solution and the other containing tap 
water, for 39 days. The concentration of the ethanol solution (v/v) was changed every 8 
days from 10% ethanol to 15% ethanol to 20% ethanol to 15% ethanol to 10% ethanol. 
Measurements of ethanol consumption (g of ethanol per kg of body weight) and water 
consumption (ml of water per kg of body weight) were recorded daily. 
Experiment 2: The effects of binge-like ethanol drinking on CRF- IR  
Each animal was assigned to one of the following groups upon arrival: water, 1-cycle, 6-
cycle, 1-sucrose, or 6-sucrose.  Animals of the water group had access to water only for the 
duration of the experiment.  Animals of the 1-cycle and 6-cycle groups were exposed to 1, or 
6 cycles of DID procedures, respectively. Each cycle of DID was separated by 3 rest days. 
To assess whether the observed changes in CRF are specific to ethanol, we assessed 
changes in CRF following consumption of a 10% sucrose solution (1-sucrose or 6-sucrose).  
Immediately following the end of 4-h ethanol access on the final day of the experiment, tail 
blood samples were collected from the tail vein of each animal given access to ethanol for 
assessment of BECs.  The tail vein of each animal given access to sucrose or water was 
nicked as a control for this procedure.   Within one hour of the end of 4-h ethanol access on 
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the final day of the experiment, all animals were perfused transcardially using procedures 
described.  All groups were matched for age at the time of perfusion.  Thus, the age at 
which the first exposure to DID procedures occurred differed between groups. 
Data Analysis 
One-way analyses of variance (ANOVAs) were used to assess differences between groups 
(1-cycle and 6-cycle) in anxiety-like behavior on the EPM and in the open field chambers, as 
well as 4-h ethanol consumption and BECs on the final day of the experiment.  Repeated 
measures ANOVAs were used to assess between-group differences in 24-h ethanol 
consumption across ethanol concentrations.  One-way ANOVAs were also used to assess 
differences between groups (1-sucrose and 6-sucrose) in 4-h sucrose consumption on the 
final day of the experiment.  Between-group differences in CRF-IR expression as a function 
of binge-like ethanol consumption (1-cycle versus 6-cycle) versus water consumption 
(water) were assessed using one-way ANOVAs.  Identical analyses were used to assess 
between-group differences in CRF-IR expression as a function of binge-like sucrose 
consumption (1-sucrose or 6-sucrose) versus water consumption (water).  Specific 
differences between groups were assessed using LSD post-hoc tests.  As the aim of the 
immunohistochemistry experiments were to assess the specific affects of binge-like ethanol 
consumption on CRF- IR, data from animals that did not achieve BECs of 80 mg/dl or 
greater are not presented (n= 4). Because unquantifiable tissue varied by animal and region 
in these experiments, the degrees of freedom may differ for each statistical analysis. 
Significance was accepted at the p < 0.05.  All data is presented as mean ± SEM. 
Results 
Experiment 1: The effects of binge-like ethanol consumption on anxiety-like behaviors and 
voluntary ethanol consumption 
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Fluid consumption. Ethanol consumption for the duration of the DID portion of this 
experiment is shown in Table 3.1. The results of a one-way ANOVA showed that the 1-cycle 
group did not differ from the 6-cycle group in binge-like ethanol consumption on the final day 
of DID (F(1, 26)= 2.486, p = 0.127). 
Anxiety-like behavior. Relative to a control group that only had a history of water intake, 
there was no effect of binge-like ethanol consumption on anxiety-like behavior (see Fig. 3.1). 
No between-group differences in open arm time (F(2, 38)= 0.146, p = 0.865), closed arm time 
(F(2, 39)= 1.056, p = 0.358) or center time (F(2, 39)= 0.913, p = 0.410) on the EPM were 
observed (see Fig. 3.1A). The number of open arm entries (F(2, 38)= 0.346, p = 0.710) and 
closed arm entries (F(2, 39)= 0.992, p = 0.380) were also not significantly different (data not 
shown). No between-group differences in the distance traveled in the margins (F(2, 39)= 
0.545, p = 0.584), distance traveled in the center (F(2, 38)= 0.867, p = 0.429), or total distance 
traveled (F(2, 39)= 0.688, p = 0.509) in the open field chamber were observed (see Fig. 3.1B).  
Voluntary ethanol consumption.  The results of a repeated measures ANOVA revealed a 
significant main effect of ethanol concentration (F(1, 37)= 66.733, p < 0.001) and a significant 
main effect of group (F(2, 37)= 10.145, p < 0.001). Post-hoc analyse performed on the group 
main effect indicated that the 6-cycle group consumed significantly more ethanol under two-
bottle choice conditions than the 1-cycle and water groups (see Fig. 3.1C).  
Experiment 2: The effects of binge-like ethanol consumption on CRF-IR and  
Fluid consumption and BECs. Consumption of ethanol during the 4-h access period for the 
duration of the experiment is shown in Table 3.1.  Immediately following the final day of the 
final DID cycle, the 1-cycle group had mean BECs of 123.28 ± 12.69 mg/dl and the 6-cycle 
group had mean BECs of 161.71 ± 17.15 mg/dl. The results of a one-way ANOVA confirmed 
that ethanol consumption and BECs on the final day of the experiment did not differ between 
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DID treatment groups, (F1,15= 0.430, p= 0.523 for ethanol consumption; F(1, 14)= 2.657, p= 
0.127 for BECs). Between-group differences in sucrose consumption on day 4 of the final 
DID cycle were not significant (F(1, 19)= 1.080, p = 0.313; mean consumption was 209.66 ± 
23.33 for the 1-suc group and 253.68 ± 42.20 for the 6-suc group). 
CRF-IR in the amygdala. Binge-like ethanol consumption significantly altered CRF-IR in the 
CeA (F(2,21)= 6.398, p= 0.008), and post-hoc analyses reveal that the 1-cycle and 6-cycle 
groups had significantly greater CRF-IR than the Water group in this region (see Figure 3.2). 
As shown in Table 3.2, binge-like ethanol consumption did not significantly affect CRF 
expression in the BLA (F(2,22)= 0.220, p= 0.804) or the MeA (F(2,23)= 0.624, p= 0.545).  CRF-
IR in each of these brain regions was not altered by sucrose consumption (F(2,20)= 3.216, p= 
0.064 for the CeA, F(2,26)= 2.214, p= 0.131 for the BLA; F(2,22)= 1.222, p= 0.316 for the MeA). 
CRF-IR in the ventral tegmental area. Figure 3.3 shows a significant effect of binge-like 
ethanol consumption on CRF-IR in the VTA (F(2,18)= 8.931, p= 0.002).  Post-hoc analyses 
reveal that the 1-cycle group displayed significantly greater CRF-IR than the water group 
and the 6-cycle group.  CRF-IR in the VTA was not altered by sucrose consumption (F(2,18)= 
0.918, p= 0.419). 
CRF-IR in the nucleus accumbens. Binge-like ethanol consumption did not significantly alter 
CRF-IR in the NAccSh (F(2,22)= 2.848, p= 0.082) or in the NAccCore (F(2,19)= 2.483, p= 
0.113). CRF-IR was not significantly altered by sucrose consumption in either of these brain 
regions (F(2,26)= 0.657, p= 0.528 for the NAccSh; F(2,24)= 1.526, p= 0.239). 
CRF-IR in the hypothalamus. Binge-like ethanol consumption did not significantly alter CRF 
expression in the PVN (F(2,23)= 1.589, p= 0.228).  Binge-like ethanol consumption did not 
have significant effects on CRF-IR in the lateral hypothalamus (LH; F(2,20)= 1.677, p= 0.215).  
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Sucrose consumption did not alter CRF-IR in either brain region (F(2,26)=1.475, p= 0.249 for 
the PVN; F(2,25)= 0.917, p= 0.414 for the LH). 
CRF-IR in the bed nucleus of the stria terminalis. Binge-like ethanol consumption did not 
affect CRF-IR in any of the sub-regions of the BNST analyzed (F(2,21)= 1.306, p= 0.294 for 
the dorsolateral BNST; F(2,20)= 1.434, p= 0.264 for the dorsomedial BNST; F(2,21)= 0.154, p= 
0.859 for the ventral BNST).  CRF-IR was not altered by sucrose consumption in any of 
these brain regions (F(2,27)= 0.220, p= 0.804 for the dorsolateral BNST; F(2,26)= 0.417, p= 
0.664 for the dorsomedial BNST; F(2,27)= 1.271, p= 0.298 for the ventral BNST). 
CRF-IR in the lateral septum (LS). Binge-like ethanol consumption did not alter CRF-IR in 
the LS (F(2,20)= 2.876, p= 0.082).  CRF-IR was not altered by sucrose consumption in this 
brain region (F(2,26)= 0.639, p= 0.536). 
CRF-IR in the pIIIu. Binge-like ethanol consumption did not alter CRF-IR in the pIIIu (F(2,18)= 
1.120, p= 0.351).  CRF-IR was not altered by sucrose consumption in this brain region 
(F(2,21)= 0.365, p= 0.699). 
 
Discussion 
 The results of the current study show that binge-like ethanol consumption altered the 
expression of CRF in two brain regions that are known to be important for drug-taking 
behaviors. Importantly, these alterations were specific to ethanol and were observed 
following as few as one cycle of binge-like drinking among animals that do not show 
behaviors consistent with ethanol dependence (i.e., heightened anxiety-like behavior during 
withdrawal and elevated ethanol consumption). Together, these findings reinforce the 
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hypothesis that binge-like drinking in non-dependent mice recruits components of the CRF 
system that have also been implicated in dependence-like drinking. 
 Numerous studies suggest that non-dependent animals do not show 
neuroadaptations in the CRF system, while ethanol dependent animals have developed 
neuroadaptations that result in augmented CRF activity following chronic ethanol exposure 
(Koob 2003; Heilig and Koob 2007; Sommer, Rimondini et al. 2008). Therefore, to 
understand our results in the context of the existing literature, it was important to assess 
whether animals undergoing DID procedures showed signs consistent with ethanol 
dependence, such as augmented anxiety-like behaviors and increased ethanol drinking 
following a period of abstinence (Koob 2003). Unlike animals following dependence-
induction by ethanol vapor exposure or ethanol diet (Koob 2003; Breese, Knapp et al. 2004; 
Knapp, Overstreet et al. 2004; Breese, Chu et al. 2005; Breese, Overstreet et al. 2005; 
Knapp, Overstreet et al. 2005), we observed no alterations in anxiety-like behavior on the 
EPM, a widely used test of anxiety, in ethanol-withdrawn mice following one or six binge-like 
drinking cycles as compared to water-drinking animals. Importantly, we observed similar null 
results using an additional test of anxiety-like behavior (the open-field chamber). With 
respect to ethanol consumption following a period of abstinence, we did not observe any 
alterations in voluntary ethanol consumption across a range of ethanol concentrations in 
mice that had undergone one binge-like drinking cycle as compared to water-drinking 
controls. However, ethanol consumption by mice that had undergone six binge-like drinking 
cycles was significantly elevated across all concentrations. Together, these results suggest 
that ethanol dependence is not likely to develop following one cycle of binge-like ethanol 
consumption, though six cycles of binge-like ethanol consumption may result in a transition 
towards ethanol dependence. Therefore, any observed alterations in CRF following one 
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cycle of binge-like ethanol consumption are not likely to stem from a state of ethanol 
dependence. 
In accordance with our hypothesis that the extrahypothalamic CRF system is 
recruited during binge-like ethanol consumption, we found that CRF-IR was significantly 
increased in the CeA and the VTA of non-dependent binge-like drinking animals. 
Importantly, these CRF in each of these brain regions is known to modulate drug self-
administration (Wang, Shaham et al. 2005; Funk, O'Dell et al. 2006; Heilig and Koob 2007; 
Bonci and Borgland 2009). Though increases of CRF-IR may reflect increased CRF activity 
(via increased CRF sysnthesis and/or release) or decreased CRF activity (via decreased 
CRF release), we are confident that our observations indicate an increase in CRF activity 
during binge-like ethanol consumption because of the converging results from the 
pharmacological and electrophysiological data (see Chapters 2, 4-5). With respect to the 
CeA, animals that underwent one or six binge-like drinking cycles had significantly increased 
CRF-IR as compared to ethanol naïve water-drinking control animals. Increases of CRF-IR 
were observed in the VTA of animals that underwent one (but not 6) binge-like drinking 
cycles. These findings demonstrate that binge-like ethanol consumption engages the CRF 
system in a manner that is dependent on the number of binge-like drinking cycles and on 
brain region, as other regions that have been previously implicated in ethanol drinking (i.e., 
the hypothalamus, BNST, and nucleus accumbens) did not show significant alterations of 
CRF-IR in response to binge-like ethanol consumption. 
To the best of our knowledge, the results of the current experiment provide the first 
evidence that ethanol exposure alters CRF expression in the VTA. Specifically, we found 
that one binge exposure cycle, but not six binge exposure cycles, resulted in significant 
increases of CRF-IR as compared to water drinking control animals. Previous studies have 
shown a role for CRF of the VTA in the modulation of cocaine-related behaviors (Wang, 
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Shaham et al. 2005; Wang, You et al. 2007), which may be due to CRF’s neuromodulatory 
effects on dopaminergic and glutamatergic transmission within this region (Wise and 
Morales 2010). Indeed, ethanol has known actions on dopaminergic and glutamatergic 
systems of the VTA (Stuber, Hopf et al. 2008; Wanat, Sparta et al. 2009; Xiao, Shao et al. 
2009; Morzorati, Marunde et al. 2010), and so it is possible that CRF modulates ethanol-
related behaviors, such as consumption, by these mechanisms. Though further investigation 
of the behavioral significance of CRF in the VTA to ethanol consumption is needed, recent 
evidence suggests that an interaction between ethanol history and CRF in the VTA has 
functionally significant consequences on intracellular signaling (Bernier, Whitaker et al. 
2011). 
 Many previous reports indicate that long-term ethanol exposure is associated with 
alterations of CRF markers in the CeA, an area that is considered integral to ethanol 
dependence (Lack, Floyd et al. 2005; Funk, O'Dell et al. 2006; Roberto, Cruz et al. 2010). 
For example, increases of pre-pro CRF mRNA were observed in the CeA of animals that 
had undergone chronic exposure to ethanol via consumption of an ethanol diet and had 
BECs of approximately 150 mg/dl at the time of sacrifice (Lack, Floyd et al. 2005). 
Additionally, significant elevations of dialysate CRF levels were observed in chronically 
exposed animals beginning 6-8 hours into ethanol withdrawal (Pich, Lorang et al. 1995), and 
decreases in CRF-IR were observed in the CeA of ethanol dependent animals following 
multiple ethanol withdrawal periods as compared to animals that did not experience 
dependence-inducing procedures (Funk, O'Dell et al. 2006). In agreement with these 
reports, we found significant elevations of CRF-IR in the CeA following 1 or 6 cycles of 
binge-like drinking. In contrast with previous reports in which non-dependent animals did not 
show elevations of CRF-IR, we also observed elevations of CRF-IR following one binge-like 
drinking episode. These results show, for the first time, that the CRF system is engaged with 
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little ethanol exposure (i.e., 1 binge exposure cycle) in animals that are unlikely to be 
ethanol dependent. As we found that 6 cycles of binge-like drinking promoted increases of 
subsequent voluntary ethanol consumption (consistent with models of dependence-like 
ethanol drinking), it is possible the mice in our 6 cycle binge-like ethanol group were in the 
process of transitioning to dependence. 
 In contrast with previous investigations that have demonstrated ethanol-induced 
changes in CRF markers (i.e., IR, heteronuclear RNA, pre-pro mRNA or mRNA) in the PVN 
of the hypothalamus (see Lowery and Thiele 2009 for review), we did not observe 
alterations of CRF-IR following binge-like ethanol consumption. It is perhaps unsurprising 
that we did not observe changes in CRF-IR in the PVN following binge-like ethanol 
consumption as our animals were consuming ethanol over the course of at least 4 days. 
Thus, they were beyond the point of acute ethanol exposure, when changes in CRF in the 
PVN are normally observed. Additionally, animals of the current study voluntary consumed 
ethanol whereas previous investigations involved experimenter-administered injections of 
ethanol which may activate CRF of the PVN in response to the stress of the procedure 
rather than in response to ethanol alone.  For example, studies suggest that CRF 
expression is increased in response to acute ethanol administration (i.e., injection or in vitro 
exposure) in the PVN of the hypothalamus (Redei, Branch et al. 1988; Rivier and Lee 1996; 
Lee, Selvage et al. 2004), perhaps reflecting an activation of the classical HPA axis stress 
response. Importantly, these data provide further evidence that CRF of extrahypothalamic 
pathways, rather than CRF of hypothalamic pathways, are involved in high levels of ethanol 
consumption. 
The allostasis hypothesis suggests that the CRF system of the extended amygdala, 
and the CeA in particular, is recruited over the course of ethanol consumption such that the 
CRF system is integral to dependence-induced elevations of ethanol consumption, but is not 
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necessary for basal, non-dependence-induced ethanol consumption (Koob 2003). According 
to this hypothesis, elevated ethanol consumption stemming from dependence functions to 
alleviate the negative affect that stems from an upregulation of CRF signaling in the CeA. 
Upregulations of CRF signaling have been observed during withdrawal from ethanol and are 
suggested to result from multiple exposures to and multiple withdrawals from ethanol over 
the course of an extended ethanol history (Koob 2003; Funk, O'Dell et al. 2006). The current 
data extend this hypothesis by suggesting that the amount of ethanol consumed during a 
period of drinking may determine whether the CRF system of the CeA is recruited. 
Specifically, irrespective of ethanol history, high levels of ethanol consumption that generate 
BECs in excess of a certain threshold (i.e., 80 mg/dl) may recruit the CRF system, while 
lower levels of ethanol consumption that generate BECs below this threshold (i.e., 40 mg/dl 
or below) do not. Additionally, while previous studies have observed increased CRF 
expression during ethanol withdrawal (Funk, O'Dell et al. 2006), the current data show that 
CRF is enhanced during drinking and so it appears that CRF expression is enhanced under 
conditions of high BECs and, as shown previously, remains elevated during ethanol 
withdrawal. Therefore, the presence of high levels of ethanol appears to recruit the CRF 
system, as does withdrawal from ethanol after an extended history of ethanol exposure.  
In sum, the current data suggests that binge-like ethanol consumption increases 
CRF-IR in the CeA and the VTA. These effects are specific to ethanol, as binge-like sucrose 
consumption does not alter CRF-IR, and are dependent on the number of binge cycles. In 
light of other data showing enhanced CRF expression in dependent animals during 
withdrawal, it appears that not only the duration of ethanol history, but the amount of ethanol 
consumed during single episodes of drinking may be an important factor in the recruitment 
of the CRF system and ultimately, the development of ethanol dependence. Subsequent 
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chapters will test the hypothesis that binge-like ethanol consumption requires the 
extrahypothalamic CRF system, but not the hypothalamic CRF system. 
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Table 3.1.  Mean binge-like ethanol (g/kg/4h ± SEM) consumption on day 4 of each DID 
cycle for the duration of each experiment. 
 
 Experiment: Anxiety-like behavior 
and two-bottle choice ethanol 
consumption following binge-like 
drinking 
 
Experiment: CRF-IR immediately 
following binge-like drinking 
  
1-cycle 
 
6-cycle 
  
1-cycle 
 
6-cycle 
 
Cycle 1 
 
 
-- 
 
 
5.55 ± 0.37 
  
-- 
 
 
5.62 ± 0.38 
Cycle 2 -- 
 
6.17 ± 0.25  -- 
 
6.02 ± 0.40 
Cycle 3 -- 
 
6.34 ± 0.27  -- 
 
6.01 ± 0.31 
Cycle 4 -- 
 
6.26 ± 0.23  -- 
 
6.70 ± 0.19 
Cycle 5 -- 
 
5.62 ± 0.27  -- 
 
6.45 ± 0.31 
Cycle 6 
 
5.05 ± 0.45 6.05 ± 0.29  5.81 ± 0.35 6.63 ± 0.34 
 Table 3.2.  Average CRF-IR (% area ± SEM) immediately following binge-like ethanol consumption. 
  
BLA 
 
MeA 
 
NAccCore 
 
NAccSh 
 
PVN 
 
LH 
 
dlBNST 
 
dmBNST 
 
vBNST 
 
LS 
 
Water 
 
 
0.02 ± 0.01 
 
0.07 ± 0.03 
 
0.06 ± 0.02 
 
0.05 ± 0.02 
 
0.11 ± 0.04 
 
0.07 ± 0.03 
 
0.15 ± 0.05 
 
0.08 ± 0.03 
 
0.06 ± 0.02 
 
0.07 ± 0.03 
1-cycle 
 
0.02 ± 0.01 0.08 ± 0.03 0.06 ± 0.02 0.09 ± 0.03 0.09 ± 0.03 0.07 ± 0.02 0.13 ± 0.05 0.10 ± 0.04 0.06 ± 0.02 0.08 ± 0.03 
6-cycle 
 
0.02 ± 0.01 0.09 ± 0.03 0.10 ± 0.04 0.15 ± 0.05 0.14 ± 0.04 0.10 ± 0.04 0.21 ± 0.08 0.12 ± 0.04 0.06 ± 0.02 0.13 ± 0.05 
F-statistic 0.220 
 
0.624 2.483 2.848 1.589 1.677 1.306 1.434 0.154 2.876 
p value 0.804 0.545 0.113 0.082 0.228 0.215 0.294 0.264 0.859 0.082 
Note: BLA, basolateral nucleus of the amygdala; MeA, medial amygdala; NAccCore, nucleus accumbens core; NAccSh, nucleus accumbens shell; PVN, paraventricular nucleus of 
the hypothalamus; LH, lateral hypothalamus; dlBNST, dorsolateral bed nucleus of the stria terminalis; dmBNST, dorsomedial bed nucleus of the stria terminalis; vBNST, ventral bed 
nucleus of the stria terminalis; LS, lateral septum; n= 5-8 per group. 
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Figure 3.1. Effects of one or six cycles of binge-like ethanol consumption on anxiety-like 
behavior in the elevated plus maze (A), anxiety-like behavior in the open field chamber (B), 
or 24h ethanol consumption under two bottle choice conditions across a range of ethanol 
concentrations (C). Values shown are mean ± SEM, and n= 13-14 per group. * denotes 
significant differences from the Water group. 
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Figure 3.2. Representative photomicrographs (40x) from the Water group (A) and the 1-
cycle group (B) showing CRF-IR in the CeA.  C) Effects of one or six cycles of binge-like 
ethanol consumption on mean CRF-IR in the CeA. Values shown are mean ± SEM, and n= 
5-8 per group. * denotes significant differences from the Water group. Scale bars, 50 µm. 
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Figure 3.3. Representative photomicrographs (40x) from the Water group (A) and the 1-
cycle group (B) showing CRF-IR in the VTA.  C) Effects of one or six cycles of binge-like 
ethanol consumption on mean CRF-IR in the VTA. Values shown are mean ± SEM, and n= 
5-8 per group. * denotes significant differences from the Water group, and + denotes 
significant differences from the 6-cycle group. Scale bars, 50 µm. 
 
 
 
 
 
 
 CHAPTER 4 
THE ROLE OF HYPOTHALAMIC CRF IN BINGE-LIKE ETHANOL CONSUMPTION BY 
C57BL/6J MICE 
 
 
Introduction 
 
Central CRF coordinates neuroendocrine and behavioral responses via two 
pathways, the extrahypothalamic pathway and the hypothalamic pathway (Hauger, 
Risbrough et al. 2006). The hypothalamic CRF pathway, which stimulates the hypothalamic-
pituitary-adrenal (HPA) axis, is considered the classical stress response. Converging 
evidence suggests that CRF stimulates the HPA axis via CRF1Rs in the hypothalamus, 
while the CRF2R is thought to be important for recovery from stress (Carrasco and Van de 
Kar 2003). In response to a stressor, CRF from the hypothalamus activates the release of 
adrenocorticotropin hormone (ACTH) from the pituitary and the subsequent release of 
glucocorticoids, such as corticosterone, from the adrenal glands. Glucocorticoids provide 
negative feedback to the hypothalamus and pituitary to terminate the stress response (Yao, 
Schulkin et al. 2008). Glucocorticoids also positively modulate other neurochemicals, 
including extrahypothalamic CRF and dopamine (Yao, Schulkin et al. 2008). 
Numerous investigations suggest a role for the HPA axis in ethanol consumption. For 
example, ethanol administration is associated with upregulation of CRF markers in the 
hypothalamus (Rivier and Lee 1996; Li, Kang et al. 2005; Richardson, Lee et al. 2008) and 
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increased circulation of ACTH (Ogilvie, Lee et al. 1997) and corticosterone (Patterson-
Buckendahl, Kubovcakova et al. 2005). Additionally, impaired HPA axis activity induced by 
surgical adrenalectomy or by pretreatment with a corticosterone synthesis inhibitor reduced 
ethanol consumption (Fahlke, Engel et al. 1994; Fahlke, Hard et al. 1994; Fahlke, Hard et al. 
1995) and corticosterone replacement reversed the effects of adrenalectomy on ethanol 
consumption (Fahlke, Hard et al. 1995).  
The findings of the investigations described in previous chapters have demonstrated 
a role for CRF signaling via the CRF1R in binge-like ethanol consumption. Given the role of 
CRF in binge-like ethanol consumption and the evidence suggesting that the HPA axis 
modulates ethanol consumption, it is possible that CRF modulates binge-like ethanol 
consumption via hypothalamic CRF1Rs and the activation of the HPA axis. Therefore, the 
goal of the current specific aim was to characterize the role of the HPA axis in binge-like 
ethanol consumption. First, we assessed the effects of reduced glucocorticoid signaling on 
binge-like ethanol consumption using a glucocorticoid receptor antagonist and a 
corticosterone synthesis inhibitor. We then assessed the effects of binge-like ethanol 
consumption on plasma corticosterone levels using radioimmunoassay. Finally, we 
assessed the effects of a CRF1R antagonist on binge-like ethanol consumption by 
adrenalectomized (ADX) animals. Here, we show that binge-like ethanol consumption does 
not require intact HPA axis signaling, as pharmacological and/or surgical adrenalectomy did 
not selectively alter binge-like ethanol consumption. Additionally, binge-like ethanol 
consumption did not alter plasma corticosterone levels, and the CRF1R antagonist-induced 
reduction of binge-like ethanol consumption did not require normal HPA axis signaling. 
Together, these results provide compelling evidence against a role for the HPA axis in 
binge-like ethanol consumption. 
Methods 
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Animals 
Male C57BL/6J mice (Jackson Laboratories, Jackson, MS) were 6-8 weeks of age and 
weighed 18-26 grams upon arrival, and male C57BL/6J mice that underwent adrenalectomy 
(ADX; n = 24; Jackson Laboratories, Bar Harbor, ME) or sham surgery (SHAM; n = 40; 
Jackson Laboratories, Bar Harbor, ME) were 8-10 weeks of age and weighed 15-26 grams 
upon arrival. As per instructions provided by Jackson Laboratories, ADX (and SHAM) mice 
were given access to a 0.9% saline solution for the first 4 days after arrival to help maintain 
sodium chloride balance. Mice were individually housed in plastic cages, were allowed to 
habituate to their environment for at least one week prior to the start of the experiments, and 
had ad libitum access to standard rodent chow and water except where noted.  The colony 
room was maintained at approximately 22°C with a 12 h light/ 12 h dark cycle and lights 
went off at 10 AM.  All procedures used are in accordance with the National Institute of 
Health guidelines, and were approved by the University of North Carolina Institutional 
Animal Care and Use Committee. 
Drugs 
Ethanol (20% v/v) solutions were prepared using tap water and 100% ethyl alcohol (Decon 
Laboratories, Inc, King of Prussia, PA) and sucrose (w/v) solutions were prepared using tap 
water and D-sucrose (Fisher Scientific, Fair Lawn, NJ).  The corticosterone synthesis 
inhibitor, 2-Methyl-1,2-di-3-pyridyl-1-propanone (metyrapone; Sigma-Aldrich, Saint Louis, 
MO) was suspended in 0.5% carboxymethylcellulose (CMC; Sigma-Aldrich, Saint Louis, 
MO) and was injected intraperitoneally (i.p; vehicle, 50, 100, or 150 mg/kg) approximately 30 
minutes prior to the start of behavioral testing.  The time course and dose range were based 
on previous data (O'Callaghan, Croft et al. 2005; Nair and Bonneau 2006).  Importantly, 
metyrapone has been shown to effectively deplete circulating plasma corticosterone levels 
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under basal (Laborie, Bernet et al. 1995; Laborie, Bernet et al. 1997) and stressed (Krugers, 
Maslam et al. 2000) conditions.  The glucocorticoid receptor antagonist mifepristone (also 
called RUCN38486; Sigma-Aldrich, Saint Louis, MO) was suspended in 0.5% CMC and 
dissolved by sonicating for 15 minutes, and was delivered i.p. (vehicle, 25, 50, or 100 
mg/kg) approximately 30 minutes prior to the start of behavioral testing.  Similar doses and 
time courses have been used previously (Roberts, Lessov et al. 1995; Koenig and Olive 
2004; O'Callaghan, Croft et al. 2005).  Mifepristone displays high binding affinity for the 
glucocorticoid type I receptor (Ki= 0.4 nM), and mifepristone and its active metabolites are 
known to cross the blood brain barrier (Heikinheimo, Pesonen et al. 1994; Peeters, Tonnaer 
et al. 2004).  The selective CRF1R antagonist, CP-154,526 (butyl-[2,5-dimethyl-7-(2,4,6-
trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-ethylamine) (CP-154,526; Pfizer, Groton, 
CT) was suspended in 0.5% CMC and injected approximately 60 minutes prior to the start of 
behavioral testing, as previously described (Sparta, Sparrow et al. 2008).  This drug is 
bioavailable, crosses the blood brain barrier, and is highly selective for the CRF1R (K1= 2.1 
nM) versus the CRF2R (Ki> 10 µM) (Schulz, Mansbach et al. 1996; Chen, Mansbach et al. 
1997; Keller, Bruelisauer et al. 2002).   
“Drinking in the Dark” (DID) Procedure 
A 4-day DID procedure was used in all experiments (Rhodes, Best et al. 2005; Sparta, 
Sparrow et al. 2008).  On days 1-3, beginning 2.5 h into the dark cycle, water bottles were 
removed from all cages.  For all experiments involving i.p. drug administration, animals were 
weighed and injected with the appropriate volume (5 ml/kg) of the specified vehicle to 
habituate them to injections.  Beginning 3 h into the dark cycle, small ethanol bottles (or 
water bottles, where specified) were weighed and placed on cages for 2 h.  The same 
schedule was followed on day 4, except that ethanol access was extended to 4 h and 
immediately thereafter, tail blood samples were collected for analysis of BECs.  For all 
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experiments involving drug administration, animals were pretreated with the appropriate 
dose of drug before the ethanol access period on day 4.  
Blood Ethanol Concentration 
Approximately 10 µl of blood was collected from the tail vein of each mouse immediately 
following ethanol access on day 4 of the DID procedure to analyze for blood ethanol 
concentration.  Samples were centrifuged, and 5 µl of plasma from each sample was 
analyzed (Analox Instruments, Lunenburg, MA). 
Experiment 1: Effects of mifepristone and metyrapone on binge-like ethanol consumption 
Mice were assigned to groups equated for ethanol consumption during the first three days of 
DID procedures, and on day 4 each group was given i.p. injections of mifepristone or vehicle 
as described above. Approximately two weeks later, these animals underwent a second 
round of DID procedures, as the mifepristone manipulation had no effect on DID ethanol 
intake (see results below).  Mice were redistributed into groups equated for ethanol 
consumption on days 1-3. On day 4, mice were given i.p. injection of metyrapone or vehicle 
as described above.  The effects of metyrapone on 4 h consumption of a 10% sucrose 
solution were assessed in an additional set of ethanol naïve animals.  Since peak brain 
levels of mifepristone and its metabolites are achieved within 1-2 hours and are eliminated 
by 4 hours following peripheral administration (Heikinheimo, Pesonen et al. 1994), an 
additional set of ethanol-naïve mice underwent DID procedures as described above except 
that ethanol consumption was measured hourly throughout ethanol access on day 4.   
Experiment 2: The effects of binge-like ethanol consumption on plasma corticosterone levels 
Ethanol naïve mice were divided into two groups equated for body weight upon arrival.  
During the 4-day DID procedure, one group was given access to a 20% ethanol solution 
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while the second group received water. Approximately 20 µl of blood was collected from the 
tail vein of each mouse immediately following the 4 h session on day 4 (7 h into the dark 
cycle).  Samples were centrifuged, and plasma was removed and frozen at -20°C.  Plasma 
corticosterone levels were assessed using 10 µl of plasma from each sample and a 
Radioimmuno Assay Kit (MP Biomedicals, Solon, OH) (Salling, Faccidomo et al. 2008). 
Experiment 3: The effects of a CRF1R antagonist on binge-like drinking by ADX and SHAM 
animals 
ADX and SHAM mice were divided into groups equated for ethanol consumption during the 
first three days of the procedure, and were given i.p. injections of vehicle or CP-154,526 on 
day 4 (vehicle, 10, or 15 mg/kg).  Two days later, the effects of adrenalectomy on 4 h 
consumption of a 3% sucrose solution were assessed in these mice. 
Statistical Analysis  
For all experiments, the first three days of ethanol consumption were analyzed using 
repeated measures analyses of variance (ANOVAs), and the fourth day of ethanol (or 
sucrose) consumption and BECs were assessed using ANOVAs. When significant 
differences were observed, follow-up Bonferroni post-hoc analyses were performed.  A 
repeated measures ANOVA was performed to assess the hourly effects of mifepristone 
(hour x dose) over the 4 hour test in which hourly measures were collected.  The 
relationship between day 4 ethanol consumption and plasma corticosterone concentrations 
was assessed with Pearson’s R correlations.  In some cases, the amount of blood sample 
collected for BEC analyses were not adequate, and therefore were not included in the 
analyses. All data are expressed as mean ± SEM, and significance was accepted at the p < 
0.05 level (two-tailed) for ANOVA and Bonferroni tests. 
Results 
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Experiment 1a: The effects of mifepristone on binge-like ethanol consumption 
Ethanol consumption during the first three days of the DID procedure did not differ based on 
drug-treatment grouping (F(3, 36)= 0.005, p = 0.999).  As shown in Figure 4.1A, ethanol 
consumption on the fourth day of the DID procedure was not altered by drug treatment (F(3, 
37)= 0.431, p = 0.732).  Blood ethanol concentrations did not differ between drug treatment 
groups (F(3, 37)= 0.220, p = 0.882; see Figure 1B).  Likewise, hourly ethanol consumption on 
the fourth day of the DID procedure was not altered by drug treatment (F(2, 27)= 0.637, p = 
0.536; data not shown).  Ethanol consumption did differ by hour (F(31, 81)= 10.552, p< 0.001), 
though the interaction between drug treatment and hour was not significant (F(6, 81)= 1.070, p 
= 0.387). 
Experiment 1b: The effects of metyrapone on binge-like ethanol consumption 
Ethanol Consumption. Ethanol consumption during the first three days of the DID procedure 
did not differ based on drug-treatment grouping (F(3, 32)= 0.922, p = 0.922).  As shown in 
Figure 4.2A, ethanol consumption on day 4 was significantly and dose-dependently altered 
by drug treatment (F(3, 35)= 16.468, p <0.001), as were blood ethanol concentrations (F(3, 34)= 
11.200, p <0.001; see Figure 4.2B).  Bonferroni post-hoc analyses reveal that animals 
pretreated with 100 mg/kg or 150 mg/kg of metyrapone consumed significantly less ethanol 
than animals pretreated with vehicle, and achieved significantly lower blood ethanol 
concentrations. 
Sucrose Consumption.  Consumption of a 10% sucrose solution was significantly altered by 
pretreatment with metyrapone, as confirmed by the results of a one-way ANOVA (F(2, 22)= 
13.055, p < 0.001.; see Figure 4.2C).  Bonferroni post-hoc analyses reveal that animals 
pretreated with 100 mg/kg or 150 mg/kg consumed significantly less of the 10% sucrose 
solution than animals pretreated with vehicle. 
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Experiment 3:  The effects of binge-like ethanol consumption on plasma corticosterone 
levels 
As shown in Figure 4.3A, plasma corticosterone levels were not significantly altered by 
ethanol consumption as compared to water consumption after 4 hours of ethanol access 
(F(1, 29)= 0.202, p = 0.657).  Plasma corticosterone levels were not significantly correlated 
with ethanol consumption (r= -0.12, p =0.330; see Figure 4.3B). 
Experiment 4: The effects of CP-154,526 and ADX on binge-like ethanol consumption 
Body weight. A repeated measures ANOVA was performed on body weight data over the 4 
days of DID procedures to determine if ADX had a negative impact on the health of mice. 
Relative to SHAM treated mice (22.73 + 0.27 g), ADX mice (22.24 + 0.35 g) did not show 
altered body weight over the 4 day procedure, suggesting that ADX mice remained healthy 
over the course of the experiment.  
Ethanol Consumption.  The results of a repeated measures ANOVA reveal a significant 
main effect of surgery on ethanol consumption during the first three days of the DID 
procedure (F(1, 58)= 9.995, p = 0.002; see Figure 4A), but no effect based on drug-treatment 
grouping (F(2, 58)= 0.027, p = 0.973; data not shown).    As shown in Figure 4.4B, 
pretreatment with CP-154,526 significantly altered ethanol consumption by both ADX and 
SHAM animals on day 4 (F(2, 58)= 13.827, p <0.001).  The main effect of surgery and the 
interaction between surgery condition and drug treatment were not significant on day 4 
(surgery condition: F(1, 58)= 3.090, p = 0.084; surgery condition x drug treatment: F(2, 28)= 
1.332, p = 0.272).  Bonferroni post hoc analyses reveal that pretreatment with either the 10 
mg/kg or 15 mg/kg dose of CP-154,526 significantly attenuated ethanol consumption 
relative to vehicle treatment in both ADX and SHAM animals. Results indicated a significant 
main effect of surgery (F(1, 58)= 6.323, p= 0.015), in addition to a significant main effect of 
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drug (F(2, 58)= 8.724, p <0.001), on BECs achieved on day 4 of the DID procedure.  The 
interaction between these two factors was not significant (F(2, 58)= 0.045, p = 0.956).  
Bonferroni post hoc analyses reveal that ADX animals achieved lower blood ethanol 
concentrations relative to SHAM animals (see Figure 4.4C).  In agreement with the ethanol 
consumption data, Bonferroni post hoc analyses also reveal that pretreatment with either the 
10 mg/kg or 15 mg/kg doses of CP significantly attenuated blood ethanol concentrations in 
both ADX and SHAM animals. 
Sucrose Consumption.  Consumption of a 3% sucrose solution was significantly attenuated 
in ADX animals relative to SHAM animals (F(1, 62)= 12.153, p= 0.001; see Figure 4.4D).  
 
Discussion 
The present results are not consistent with a role for HPA axis signaling in the 
modulation of binge-like drinking, and show that the effects of CRF1R antagonism on binge-
like drinking does not require normal HPA axis function. These conclusions are based on 
the following observations: 1) manipulation of the HPA axis independent of CRF antagonism 
(i.e., blockade of glucocorticoid receptor or inhibition of corticosterone synthesis with 
administration of metyrapone or ADX) failed to selectively protect against binge-like ethanol 
consumption, 2) binge-like ethanol drinking did not influence plasma corticosterone levels in 
mice, and 3) pretreatment with CP, a CRF1R antagonist, attenuated ethanol consumption to 
a similar degree in both ADX- and SHAM-treated mice, showing that CP-induced reduction 
of binge-like ethanol drinking does not require normal HPA axis signaling.  
Reduced corticosterone signaling via pretreatment with metyrapone or 
adrenalectomy reduced both binge-like ethanol consumption and binge-like sucrose 
consumption. These results suggest a role for the HPA axis in reward, as both ethanol and 
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sucrose have reinforcing properties, and are in agreement with previous studies indicating 
that adrenalectomy reduces both voluntary ethanol (Fahlke, Hard et al. 1995) and sucrose 
consumption (Seidenstadt and Eaton 1978).  Metyrapone has also been shown to reduce 
ethanol consumption at similar doses (Fahlke, Hard et al. 1994; O'Callaghan, Croft et al. 
2005), and corticosterone signaling has been implicated in the self-administration of other 
drugs of abuse, including cocaine (Goeders and Guerin 1996; Goeders and Guerin 2008) 
and amphetamine (Piazza, Maccari et al. 1991). When taken together, these data are 
consistent with a role for HPA axis signaling in the self-administration of substances with 
reinforcing properties rather than specifically in the modulation of ethanol consumption. 
The second point suggesting that HPA axis signaling is not necessary for the 
expression of binge-like ethanol drinking is the observation that pretreatment with 
mifepristone, a glucocorticoid receptor antagonist, did not alter binge-like ethanol 
consumption at any of the doses tested.  Although one investigation did report dose-
dependent attenuation of 1-h ethanol consumption following peripheral pretreatment with 1-
20 mg/kg doses of mifepristone (Koenig and Olive 2004), several other investigations, in 
addition to the present report, have found that blockade of glucocorticoid receptors does not 
alter ethanol consumption (Fahlke, Hard et al. 1995; Fahlke, Hard et al. 1996; O'Callaghan, 
Croft et al. 2005; Yang, Wang et al. 2008).  While it has been reported that mifepristone is 
rapidly metabolized in several species, including rats (Peeters, Tonnaer et al. 2004), it is 
unlikely that this factor accounts for the observed lack of effect on binge-like ethanol drinking 
because hourly measurements of binge-like ethanol drinking also failed to show an effect of 
mifepristone.  Based on the study by Koenig & Olive (2004), it is possible that mifepristone 
would have effectively reduced binge-like ethanol consumption had a lower dose range 
been employed.  However, this is unlikely since attenuation of ethanol consumption was 
greatest at the highest dose tested (20 mg/kg; Koenig and Olive 2004), yet no alterations in 
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ethanol consumption were observed after administration of a 25 mg/kg dose of mifepristone 
in the current study.  Furthermore, the literature indicates that mifepristone is most 
efficacious at high doses when administered peripherally since this compound does not 
readily cross the blood brain barrier (Peeters, Tonnaer et al. 2004). While the factors that 
contribute to the inconsistencies between the Koening & Olive (2004) study and the present 
report are not clear, one straightforward interpretation is the glucocorticoid receptor 
signaling modulates limited access ethanol consumption by rats, but not binge-like ethanol 
drinking in C57BL/6J mice. 
The third point suggesting that HPA axis signaling does not modulate binge-like 
drinking is the observation that binge-like ethanol intake did not alter circulating levels of 
corticosterone in C57BL/6J mice relative to mice drinking water. As corticosterone is often 
used as a marker of HPA axis activity (Richardson, Lee et al. 2008), these results suggest 
that binge-like ethanol consumption is not driven by heightened HPA axis activity.  Although 
4-h of binge-like ethanol drinking did not alter plasma corticosterone levels in the current 
study, some reports have shown robust increases in circulating corticosterone following 
ethanol administration via multiple routes, including intravenous (Richardson, Lee et al. 
2008), intragastric (Lee and Rivier 1997; Ogilvie, Lee et al. 1997), intraperitoneal (Ogilvie, 
Lee et al. 1997), ingestion in the form of ethanol diet (Ogilvie, Lee et al. 1997), and self-
administration (Richardson, Lee et al. 2008).  While these results suggest that ethanol can 
stimulate HPA axis activity, such activity appears to be sensitive to the time of day.  The 
effects of ethanol administration on corticosterone levels have primarily been observed 
during the animals’ light cycle, when basal corticosterone levels are typically low relative to 
corticosterone levels during the dark cycle (Loh, Abad et al. 2008).  Although one recent 
report describes ethanol-induced increases in plasma corticosterone during the dark cycle 
(Richardson, Lee et al. 2008), it is difficult to draw direct comparisons with the present study 
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as different species (rats versus mice) and routes of ethanol administration (intravenous 
versus ethanol drinking) were employed.  
It should be noted that binge-like ethanol intake may have triggered an increase in 
plasma corticosterone levels, but such increases may have been transient and thus missed 
at the employed sampling time (4 h after the initiation of ethanol consumption on the 4th day 
of ethanol access). For example, it is possible that ethanol-induced increases of plasma 
corticosterone occur transiently towards the beginning of ethanol consumption and thus 
returned to baseline levels before blood samples were collected 4 hours after ethanol 
consumption began. It is also possible that mice develop tolerance to ethanol-induced 
increases of plasma corticosterone levels, and that such tolerance may have been complete 
by the 4th day of ethanol access. However, these possibilities are unlikely because ethanol-
induced elevatations of serum corticosterone have been reported 1) at least 4h following 
ethanol injection and 2) on the 10th consecutive day of ethanol exposure (Pruett, Collier et 
al. 1998). 
 Given that the HPA axis does not appear to be involved in binge-like ethanol 
consumption, the current converging results strongly suggest that extrahypothalamic CRF 
modulates binge-like ethanol consumption. A role for extrahypothalamic CRF in binge-like 
ethanol consumption are consistent with the results presented in Chapter 2, in which binge-
like ethanol consumption increased CRF expression in the CeA and the VTA, both of which 
are extrahypothalamic brain regions, but not in the PVN or the LH, sub-regions of the 
hypothalamus. Interestingly, previous reports have demonstrated the integral role of the 
extrahypothalamic CRF system in ethanol consumption associated with ethanol 
dependence using site-directed administration of CRF antagonists (Funk, O'Dell et al. 2006; 
Funk and Koob 2007). Given that binge drinking increases the risk of developing alcohol 
dependence in humans (Bonomo, Bowes et al. 2004; Jennison 2004), it is possible that the 
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recruitment of extrahypothalamic CRF during binge-like ethanol consumption leads to the 
development of pathological neuroadaptations in the CRF system that characterize ethanol 
dependence. The role of extrahypothalamic CRF in binge-like ethanol consumption will be 
investigated in the next chapter. 
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Figure 4.1. Effects of mifepristone on mean binge-like ethanol consumption (A) and mean 
BECs (B). Values shown are mean ± SEM, and n= 10 per group. *denotes significant 
difference from the vehicle group (p < 0.05). 
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Figure 4.2. Effects of metyrapone on mean binge-like ethanol consumption (A), mean BECs 
(B), and mean consumption of a 10% sucrose solution (C). Values shown are mean ± SEM, 
and n= 9 per group. *denotes significant difference from the vehicle group (p < 0.05). 
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Figure 4.3. (A) Effects of binge-like ethanol consumption on mean plasma corticosterone. 
(B) The correlation between corticosterone and ethanol consumption. Values shown are 
mean ± SEM, and n= 15 per group. *denotes significant difference from the vehicle group (p 
< 0.05). 
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Figure 4.4. (A) Effects of adrenalectomy on mean ethanol consumption on days 1-3 (n= 24-
40 per group). Effects of CP-154,526 on mean binge-like ethanol consumption (B) and 
mean BECs achieved (C) by SHAM and ADX animals. (D) Effects of adrenalectomy on 
mean consumption of a 3% sucrose solution. Values shown are mean ± SEM, and n= 8-14 
per group. *denotes significant difference from the vehicle group (p < 0.05). 
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 CHAPTER 5 
THE ROLE OF THE CRF SIGNALING IN THE CENTRAL NUCLEUS OF THE AMGYDALA 
IN BINGE-LIKE ETHANOL CONSUMPTION BY C57BL/6J MICE 
 
Introduction 
 CRF of extrahypothalamic brain regions is known to modulate many behaviors, 
including emotional responses, anxiety and drug-taking behavior (Hauger, Risbrough et al. 
2006). With respect to ethanol, many investigations have demonstrated that CRF of the 
central nucleus of the amygdale (CeA) modulates many aspects of ethanol dependence 
including increased anxiety during ethanol withdrawal and elevated dependence-induced 
ethanol consumption (Breese, Chu et al. 2005; Lowery and Thiele 2009). For example, 
administration of CRF antagonists into the CeA have been shown to attenuate withdrawal-
related anxiety and dependence-induced ethanol consumption (Rassnick, Heinrichs et al. 
1993; Overstreet, Knapp et al. 2005; Funk, O'Dell et al. 2006; Chu, Koob et al. 2007). 
Because persistent upregulations of CRF and CRF1R expression are observed in the CeA 
during withdrawal from ethanol (Merlo Pich, Lorang et al. 1995; Lack, Floyd et al. 2005; 
Funk, O'Dell et al. 2006), researchers have suggested that neuroadaptations of the CRF 
system in the CeA that develop over the course of chronic ethanol exposure underlie 
ethanol dependence (Koob 2003; Heilig and Koob 2007).  To date, the recruitment of the 
CRF system prior to the onset of ethanol dependence has not been characterized. 
 The converging evidence of the previous chapters strongly suggests a role for 
extrahypothalamic CRF in binge-like ethanol consumption. It appears that binge-like ethanol 
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consumption selectively alters CRF expression in extrahypothalamic brain regions, including 
the CeA, and that CRF1Rs are necessary for binge-like ethanol intake to occur. Given that 
binge-like drinking increases the risk of developing ethanol dependence (Bonomo, Bowes et 
al. 2004; Jennison 2004; Courtney and Polich 2009) and that CRF in the CeA is integral to 
the expression of ethanol dependence (Heilig and Koob 2007), it is possible that the CRF 
system of the CeA is initially recruited during binge-like ethanol consumption prior to the 
onset of ethanol dependence. The goal of the current specific aim was to test this 
hypothesis. We first assessed the effects of binge-like ethanol consumption on CRF 
expression and function in the CeA. We then assessed the effects of a CRF1R antagonist 
delivered into the CeA on binge-like ethanol consumption. Here, we show that a history of 
binge-like ethanol consumption disrupts CRF’s modulation of GABAergic signaling in the 
CeA despite upregulation of CRF expression. We also demonstrate that intra-CeA 
administration of a CRF1R antagonist attenuates binge-like ethanol consumption.  Taken 
together, these results suggest that the recruitment of the CRF system of the CeA during 
binge-like ethanol consumption leads to significant neuroadaptations in the structure and 
function of this system, and ultimately to a state of ethanol dependence. 
 
Methods 
Animals. 
 Male C57BL/6J mice (Jackson Laboratories, Jackson MS) were 6-8 weeks of age and 
weighed 20-30 grams upon arrival.  Mice were housed individually in plastic cages and 
allowed to habituate to the environment for at least one week before experimental 
procedures were initiated.  The animal colony room was maintained at approximately 22˚C 
with a 12h/12h light/dark cycle (lights on at 700 h or 1300 h).  Animals had ad lib access to 
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food throughout all experiments and free access to water except during ethanol access, as 
noted.  All procedures used are in accordance with the National Institute of Health 
guidelines, and were approved by the University of North Carolina Institutional Animal Care 
and Use Committee. 
 Drugs. Ethanol (20% v/v) solutions were prepared using tap water and 95% ethyl alcohol 
(Decon Laboratories, King of Prussia PA), and sucrose (10% w/v) solutions were prepared 
using tap water and D-sucrose (Fisher Scientific, Fair Lawn NJ).  The CRF1R non-peptidic 
antagonist antalarmin (Sigma-Aldrich, St. Louis MO) was dissolved in 0.9% saline and 
emulphor solution (5% emulphor v/v) and delivered approximately 1 h prior to ethanol 
access. Previous studies were used to select the dose (Robison, Meyerhoff et al. 2004; 
Wang, Fang et al. 2006) and injection volume (Finn, Snelling et al. 2007).  CRF (Tocris; 
Ellisville MO) was dissolved in dH2O to a concentration of 0.1 mM, diluted to 200 nM in 
artificial cerebrospinal fluid (ACSF) and bath applied. 
Drinking in the Dark 
 All experiments used a 4-day drinking-in-the-dark (DID) procedure (Rhodes, Best et al. 
2005; Rhodes, Ford et al. 2007).  On days 1-3, beginning 3 h into the dark cycle, water 
bottles were removed from all cages and replaced with bottles containing a 20% ethanol 
solution.  Animals had 2 h of access to ethanol, after which ethanol bottles were removed 
from cages and water bottles were replaced.  The same procedure was followed on day 4 
except that ethanol access was extended to 4 h. Immediately following 4-h ethanol access 
on day 4, approximately 10 µl of blood were collected from the tail vein of each animal.  
Blood samples were centrifuged, and 5 µl of plasma were analyzed for BECs using the 
Analox Alcohol Analyzer (Analox Instruments, Lunenburg MA). To assess the specificity of 
experimental manipulations to binge-like ethanol con
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conducted. Briefly, sucrose control studies were conducted following the DID procedure 
except that 10% sucrose solution was presented in place of 20% ethanol solution.  
Perfusions, Brain Preparation, and Immunohistochemistry (IHC) 
Immunohistochemistry procedures were based on those routinely used in our laboratory 
(Hayes, Knapp et al. 2005). Approximately 18-24 h following the final DID exposure to 
ethanol, mice were perfused transcardially with 0.1 mM phosphate-buffered saline (PBS; 
pH7.4) followed by 4% paraformaldehyde in phosphate buffer.  The brains were collected 
and post-fixed in paraformaldehyde for 48 hours at 4°C, at which point they were transferred 
to PBS. The brains were cut using a vibratome into 40 µm sections that were then stored in 
cryopreserve until the IHC assay. Sections were then transferred to PBS for 24 h before 
processing with CRF antibody. After rinsing in fresh PBS 4 times (10 minutes each), tissue 
sections were blocked in 10% goat serum and 0.1% triton-X-100 in PBS for 1 hour. Sections 
were then transferred to fresh PBS containing primary antibody for 72 h at 5°C.  CRF 
expression was detected using primary rabbit anti-CRF (Peninsula Laboratories, LLC, San 
Carlos, CA; 1:10000 as determined by pilot studies).  As a control to determine if staining 
required the presence of the primary antibodies, some sections were run through the assay 
without primary antibody. In each assay described below, tissue processed without the 
primary antibody failed to show staining that was evident in tissue processed with primary 
antibody. After the 72 h of incubation, the sections were rinsed 4 times and then processed 
with Vectastain Elite kits (Vector Labs) as per the manufacturer’s instructions for standard 
ABC/HRP/diaminobenzidine-based immunohistochemistry. The sections processed for CRF 
were visualized by reacting the sections with a 3,3′-diamino-benzidine tetrahydrochloride 
(DAB; Polysciences, Inc., Warrington, PA) reaction solution containing 0.05% DAB, 0.005% 
cobalt, 0.007% nickel ammonium sulfate, and 0.006% hydrogen peroxide. All sections were 
mounted on glass slides, air-dried overnight, and cover slipped for viewing. Digital images of 
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CRF immunohistochemistry (CRF-IR) was obtained on a Nikon E400 microscope equipped 
with a Nikon Digital Sight DS-U1 digital camera run with Nikon-provided software.  
Densitometric procedures were used to assess levels of CRF-IR and Ucn-IR in 
predetermined brain regions of interest where staining was visible.  Flat-field corrected 
digital pictures (8-bit grayscale) were taken using the Digital Sight DS-U1 camera.  For the 
CRF-IR in all brain regions of interests, the density of staining was analyzed using Image J 
software (Image J, National Institute of Health, Bethesda, MD) by calculating the percent of 
the total area examined that showed signal (cell bodies and processes) relative to a 
subthreshold background.  The size of the areas that were analyzed was the same between 
animals and groups. The subthreshold level for the images was set in such a way that any 
area without an experimenter-defined level of staining was given a value of zero. 
Anatomically matched pictures of the left and right sides of the brain were used to produce 
an average density for each brain region from each slice. In all cases, quantification of 
immunohistochemistry data was conducted by an experimenter that was blinded to group 
identity.  For analysis, great care was taken to match sections through the same region of 
brain and at the same level using anatomic landmarks with the aid of a mouse stereotaxic 
atlas (Paxinos and Franklin 2004).   
Brain slice preparation and electrophysiology. Brains were placed in ice-cold sucrose ACSF 
containing: (in mM) 194 sucrose, 20 NaCl, 4.4 KCl, 2 CaCl2, 1 Mg Cl2, 1.2 NaH2PO4, 10.0 
glucose, and 26.0 NaHCO3 saturated with 95% O2/ 5%CO2. The brains were cut using a 
vibratome into 300 µm sections and slices containing the CeA were identified using a mouse 
brain stereotaxic atlas (Paxinos and Franklin 2004). Slices were then stored in a heated (28 
°C), oxygenated (95% O 2/ 5%CO2) holding chamber containing ACSF [(in mM) 124 NaCl, 
4.4 KCl, 2 CaCl2, 1.2 MgSO4, 1 NaH2PO4, 10.0 glucose, and 26.0 NaHCO3 ] or transferred 
to a submerged recording chamber (Warner Instruments) where they were perfused with 
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heated, oxygenated ACSF at a rate of 2 ml/min. Slices were allowed to equilibriate in ACSF 
for 1 h prior to the start of experiments. Whole-cell voltage clamp recordings were conducted 
from slices in the submerged recording chamber. Neurons of the CeA were visualized using 
infrared video microscopy (Olympus). Recording electrodes (3-6 MΩ) were pulled on a 
micropipette puller (Sutter Instruments) using thin-walled borosilicate glass capillaries. To 
analyze evoked inhibitory postsynaptic currents (eIPSCs), electrodes were filled with (in 
mM) K+-gluconate (70), KCl (80), HEPES (10), EGTA (1), ATP (4), GTP (0.4) pH 7.2, 290-
295 mOsmol. Twisted nichrome wire stimulating electrodes were placed in the CeA, 100-
500 µm from the recorded neuron. After entering a whole-cell configuration, cells were held 
at -70mV and GABA type A receptor (GABAAR)-mediated IPSCs were evoked at 0.2 Hz by 
local fiber stimulation with bipolar electrodes. GABAA-IPSCs were pharmacologically 
isolated by adding 10 µM NBQX. Signals were acquired via a Multiclamp 700B amplifier 
(Axon Instruments), digitized and analyzed via pClamp 10.2 software (Axons Instruments). 
Input resistance and series resistance were continuously monitored during experiments. 
Experiments in which changes in series resistance were greater than 20% were not included 
in the data analysis. eIPSC experiments were analyzed by measuring the peak amplitude of 
the synaptic response, which was normalized to the baseline period. The baseline period 
was defined as the 2 min period immediately preceding the application of the drug. CRF 
(200 nM) was bath applied at minutes 5-20.  
Surgery and Infusion Procedures: Animals were surgically implanted with bilateral 26-gauge 
guide cannulae (Plastics One, Inc., Roanoke, VA) aimed at the CeA (0.94 mm posterior to 
bregma; 2.55 mm lateral to the midline; 2.60 mm ventral to the skull surface) using the Angle 
II stereotax (Leica Instruments Inc., Houston, TX) with the aid of a mouse stereotaxic atlas 
(Paxinos and Franklin 2004). Following surgery, DID procedures were initiated. On day 4, 
animals were injected bilaterally with antalarmin (1 µg/ 0.5 µl per side) or vehicle (5% 
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emulphor in saline; 0.5 µl per side) over 60 sec approximately 1 h prior to ethanol access 
using a 33-gauge injector designed to extend 2 mm beyond the cannula tip. A sucrose 
control study was conducted to evaluate the effects of antalarmin or vehicle on consumption 
of a 10% sucrose solution over a 4-h period beginning 3 h into the dark portion of the light 
cycle. For this control study, animals were assigned to drug treatment groups based on their 
body weights. Cannulae placements were determined for each animal using injections of 
blue dye and thionin staining of mounted sections of brain tissue. Only the data from 
animals in which both cannulae were correctly aimed at the CeA were included, and all data 
from animals in which both cannulae (n= 1) or one cannula (n= 8) did not target the CeA 
were excluded.  
Experiment 1: CRF-IR in the CeA during withdrawal from binge-like ethanol drinking.  Upon 
arrival, each animal was randomly assigned to the water group or the 3-withdrawal group. 
Animals of the water group had access to water only for the duration of the experiment.  
Animals of the 3-withdrawal group were exposed to 3 cycles of the 4-day DID procedures 
described above. Each DID cycle was separated by 3 rest days. Blood samples were 
collected from each group of mice immediately following the 4 hour test period on the final 
day of DID procedures. All animals were anesthetized and perfused transcardially 18-24 
hours into withdrawal from their final 4-h ethanol access. Brains were collected, sliced, and 
prepared for IR.  
Experiment 2: GABAergic transmission in the CeA following binge-like ethanol drinking. As 
binge-like ethanol consumption significantly affected CRF expression in the CeA, we 
assessed the effects of 3 exposures to binge-like ethanol consumption on the 
neuromodulatory activity of CRF on GABA signaling in the CeA. Upon arrival, each animal 
was randomly assigned to either the water or 3-withdrawal group. Animals of the water 
group had access to water only for the duration of the experiment. Animals of the 3-
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withdrawal group were exposed to 3 cycles of DID procedure, each of which were separated 
by 3 rest days. Blood samples were collected from both groups immediately following the 4 
hour test on the final day of DID procedures. Approximately 18-24 h following ethanol 
access, animals were anesthetized and decapitated. Brains were collected, sliced, and 
prepared for in vitro electrophysiology. 
Experiment 3: Binge-like ethanol consumption following intra-CeA microinjections of a 
CRF1R antagonist. To test the hypothesis that high levels of ethanol intake require CRF 
signaling in the CeA, the effects of microinjections of antalarmin into the CeA on binge-like 
ethanol consumption were assessed. Animals underwent 1 cycle of DID prior to undergoing 
surgery to implant bilateral cannulae aimed at the CeA to habituate them with ethanol 
drinking. Animals recovered from surgery for at least 10 days and were then habituated to 
microinjection procedures on two non-consecutive days prior to the initiation of DID 
procedures. Briefly, animals were held while the dummy headcaps were removed and 
injectors were lowered through the guide cannulae. Injectors remained in place for 1 min 
though no injection took place to avoid infection, and then the injectors were removed and 
the dummy headcaps were replaced. At least 2 days following habituation to the injection 
procedure, DID procedures were initiated as described above. Drug treatment groups were 
formed based on ethanol consumption on days 1-3. On day 4, animals were injected with 
antalarmin (1 µg/ 0.5 µl per side) or vehicle (5% emulphor in saline; 0.5 µl per side) 
approximately 1 h prior to ethanol access. A sucrose control study was conducted to 
evaluate the effects of antalarmin (1 µg/ 0.5 µl per side) or vehicle (5% emulphor in saline; 
0.5 µl per side) on consumption of a 10% sucrose solution over a 4-h period beginning 3 h 
into the dark portion of the light cycle. For this control study, animals were assigned to drug 
treatment groups based on their body weights. 
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Statistical analyses.  One-way ANOVAs were used to assess between-group differences in 
binge-like ethanol consumption and BECs, CRF-IR, and basal GABAergic signaling. 
Repeated measures ANOVAs were used to assess between-group differences in eIPSC 
peak amplitudes prior to CRF application (min 1-5) and while CRF was bath applied (min 6-
20). A Student’s t-test was used to assess the main effect of DID treatment on CRF’s 
modulation of GABAergic signaling. Because unquantifiable tissue varied by animal and 
region in Experiment 2, the degrees of freedom may differ for each statistical analysis. LSD 
post-hoc tests were used to assess specific between-group differences where appropriate. 
Significance was accepted at the P < 0.05 (two-tailed).  All data are presented as mean ± 
SEM.  
Results 
Experiment 1: CRF-IR in the CeA during withdrawal from binge-like ethanol drinking.  
Consumption of ethanol during the 4-h access period for the duration of the experiment is 
shown in Table 5.1. Figure 5.1 shows representative photomicrographs of CRF in the CeA 
of a water-drinking animal (A) and an animal from the 3-WD group (B).  Animals of the 3-WD 
group achieved mean BECs of 115.8 ± 20.72 mg/dl during the final 4-h ethanol access. A 
one-way ANOVA revealed that the 3-WD group had significantly greater CRF-IR in the CeA 
than the water group (F(1,19)= 7.586, p = 0.013; see Figure 5.1C). 
Experiment 2: GABAergic transmission in the CeA following binge-like ethanol drinking.  
Binge-like ethanol consumption on day 4 of each DID cycle is shown in Table 5.1. Animals 
of the 3-WD group achieved mean BECs of 133.48 + 10.5 mg/dl during the final 4-h ethanol 
access. Representative traces showing the effects of CRF on GABAergic transmission in a 
water-drinking animal and an animal from the 3-WD group are shown in Figure 5.2A. The 
results of a repeated measures ANOVA revealed that a history of binge-like ethanol 
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exposure lead to a significant reduction in the ability of CRF to enhance GABAergic 
transmission in the CeA (F(1, 9)= 9.163, p = 0.014; see Figure 5.2B). The results of a t-test 
revealed a significant main effect of ethanol history on the average modulation of eIPSC 
peak amplitude by CRF (t(9) = 2.445, p = 0.0370), as the average peak amplitude of IPSCs 
evoked in the presence of CRF was enhanced by 29 ± 11% in water drinking control animals 
but was not altered (-7 ± 9%) in animals with a history of binge-like ethanol consumption 
(see Figure 5.2C). In addition, to determine if there were any differences in the probability of 
basal GABA release, the paired-pulse ratio of the evoked IPSC in both water and alcohol 
exposed mice were assessed, and no significant differences were found (t(9) = 0.3392, p = 
0.74, Figure 5.2D). Together, these results suggest that the modulatory effects of CRF on 
GABAergic transmission in the CeA are blunted during withdrawal from binge-like ethanol 
consumption.  
Expeirment 3: Binge-like ethanol consumption following intra-CeA microinjections of a 
CRF1R antagonist. Our previous results suggest that CRF signaling may be engaged in the 
CeA and motivate binge-like drinking. To test this hypothesis, the effects of microinjections 
of antalarmin into the CeA on binge-like ethanol consumption were assessed. Average 
ethanol consumption and BEC data from day 4 are presented in Figure 5.3. The results of a 
one-way ANOVA revealed a significant effect of drug treatment (F(1, 14)= 8.921, p = 0.011), 
confirming that intra-CeA administration of antalarmin significantly blunted binge-like ethanol 
consumption (Figure 5.3A).  Significant between-group differences in BECs were also 
observed (F(1, 14)= 4.847, p = 0.046), as animals pretreated with antalarmin achieved 
significantly lower BECs than animals that received vehicle (Figure 5.3B). Conversely, 
pretreatment with antalarmin into the CeA did not have effects on 4-h sucrose consumption 
(F(1, 16)= 1.458, p = 0.246; Figure 5.3C). Cannula placements are shown in Figure 5.3D. 
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Discussion 
 The results of the current study provide novel evidence that the endogenous CRF 
system of the CeA is recruited during bouts of binge-like ethanol consumption by non-
dependent animals. First, a history of three binge-like ethanol drinking cycles abolished the 
ability of exogenous CRF to increase GABAergic transmission in the CeA at a time point 
when endogenous CRF was upregulated in this region (as shown by analysis of IR). 
Second, antagonism of CRF1R in the CeA attenuated binge-like ethanol consumption, but 
had no effect on sucrose consumption. Together, these converging results provide 
convincing evidence that binge-like ethanol consumption recruits the CRF system and that 
CRF signaling is necessary for maintaining the high levels of ethanol consumption that 
characterize this pathological behavior.  
 It is well-known that CRF exerts modulatory effects on GABAergic signaling in the 
CeA in a way that mirrors ethanol’s effects on GABAergic transmission (Nie, Schweitzer et 
al. 2004; Bajo, Cruz et al. 2008; Nie, Zorrilla et al. 2009; Roberto, Cruz et al. 2010). 
According to several previous studies and the current data, CRF enhances GABAergic 
transmission by neurons of the CeA in ethanol-naïve animals (Nie, Schweitzer et al. 2004; 
Bajo, Cruz et al. 2008; Nie, Zorrilla et al. 2009; Roberto, Cruz et al. 2010). Previous 
investigations show that this effect is augmented by a history of ethanol dependence in 
withdrawn animals relative to ethanol-naïve controls (Roberto, Cruz et al. 2010). The current 
results also suggest that alterations in GABAergic signaling in the CeA are due to changes 
in modulation by CRF following ethanol exposure. In contrast to findings in ethanol 
dependent animals, however, we found that a history of binge-like ethanol consumption 
abolished the ability of CRF to enhance GABAergic transmission. Indeed, among animals 
that experienced three binge-like drinking cycles, we observed a disrupted response to CRF 
at a time point when CRF-IR was upregulated relative to water-drinking controls, perhaps 
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reflecting homeostatic regulation of the CRF-GABA system in response to high brain ethanol 
concentrations. 
The divergent results of the current study and previous studies of ethanol-dependent 
animals suggest that binge-like ethanol consumption engenders different patterns of 
GABAergic transmission than does ethanol dependence due to differences between the 
CRF systems of ethanol dependent and non-dependent animals. For example, few 
exposures to high levels of ethanol (as in the current study) may cause transient 
perturbations of the CRF system that return to a homeostatic set point, while many 
exposures to high levels of ethanol (as in studies of ethanol dependent animals) may cause 
permanent adaptations in the CRF system that reflect the establishment of an allostatic set 
point. Thus, during binge-like ethanol drinking in non-dependent mice, CRF receptors may 
become desensitized to compensate for the robust increase of CRF expression observed 
during ethanol withdrawal. GABAergic activity in the CeA is known to regulate interneurons 
projecting to the medial portion of the CeA, which projects to downstream targets like the 
BNST, VTA, substantia nigra (SN) and ventral pallidum (VP) that have been implicated in 
drug-taking behaviors (Koob and Volkow ; Haber and Knutson 2009; Smith, Tindell et al. 
2009). Therefore, receptor desensitization would prevent exogenous CRF from affecting 
GABAergic transmission and downstream targets. Conversely, in previous studies showing 
enhanced effects of CRF on GABAergic transmission in dependent animals, it is possible 
that CRF receptors become sensitized over the course of dependence, thus increasing the 
effects of exogenous CRF on GABAergic interneurons of the medial CeA which would 
disinhibit downstream targets, and perhaps promote further drug-taking behavior. Future 
research will evaluate this possibility. 
Though binge-like ethanol consumption and dependence-induced ethanol 
consumption appear to fundamentally differ in some aspects, it is important to note that both 
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behaviors require CRF signaling in the CeA. Specifically, both dependence-induced ethanol 
consumption and binge-like ethanol consumption are attenuated by microinjections of a 
CRF receptor antagonist (Funk, O'Dell et al. 2006) or a CRF1R antagonist (the present 
study), respectively, in to the CeA. When these two findings are considered in tandem with 
evidence showing that CRF antagonists do not alter ethanol consumption by low drinking 
and/ or non-dependent animals, it is reasonable to suggest that the determining factor in the 
recruitment of CRF may be the BECs achieved during bouts of ethanol drinking, rather than 
the extent of ethanol history and withdrawal as previously suggested (Koob 2003). 
Furthermore, these results suggest that the recruitment of the CRF system during a potential 
binge may drive further ethanol drinking to levels of binge-like intake, and, in accordance 
with the allostasis model of alcoholism (Koob 2003), it is likely that repeated episodes of 
binge-like ethanol drinking culminate in plastic neuroadaptations in this neurocircuitry that 
underlie ethanol dependence. The observation that both ethanol-dependent animals (Funk, 
O'Dell et al. 2006) and animals with a history of binge-like ethanol consumption show 
increased CRF expression in the CeA during withdrawal further supports these hypotheses. 
Together, the results of the current study reveal the following novel observations: 1) 
CRF signaling via the CRF1R is necessary for episodes of drinking that yield high BECs 
(i.e., >80 mg/dl), 2) recruitment of the CRF system during episodes of drinking that yield 
high BECs has significant consequences on future drinking behavior and on CRF’s 
modulation of downstream targets, and 3) CRF1R signaling in the CeA contributes to high 
levels of ethanol consumption that results in high BECs even during the early stages of 
ethanol experience. These groundbreaking findings not only demonstrate a manner by 
which CRF signaling is recruited before the development of dependence, but also suggest 
that CRF1R antagonists may be used in a prophylactic capacity attenuate binge drinking by 
at-risk individuals in hopes of avoiding alcohol dependence altogether. 
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Table 5.1. Mean binge-like ethanol consumption (g/kg/4h ± SEM) on day 4 of each DID 
cycle for the duration of each experiment. 
 
 
  Experiment 1  Experiment 2 
 
Cycle 1 
 
 5.37 ± 0.31  5.64 ± 0.41 
 
Cycle 2 
 
 5.39 ± 0.23  6.07 ± 0.31 
 
Cycle 3 
 
 5.27 ± 0.38  5.27 ± 0.34 
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Figure 5.1. Representative photomicrographs from the Water group (A) and the 3-WD group 
(B) showing CRF-IR in the CeA following 18-24 h of ethanol withdrawal. (C) Effects of water 
drinking or 3 cycles of binge-like ethanol consumption on CRF-IR in the CeA following 18-24 
h of ethanol withdrawal. Values shown are mean ± SEM, and n= 10 per group. * denotes 
significant differences from the Water group. Scale bars, 50 µm. 
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Figure 5.2. (A) Representative traces show that CRF significantly enhanced eIPSCs relative 
to baseline IPSCs in a slice from the water group, an effect which was abolished in a slice 
from the 3-WD group. (B) Bath application of CRF to slices containing the CeA enhanced 
mean eIPSC peak amplitudes (percent of baseline) of the water group. This effect was 
abolished in the 3-WD group. (C) Bath application of CRF enhanced eIPSC peak amplitudes 
of the water group by more than 20%, but did not alter the eIPSC peak amplitudes of the 3-
WD group. (D) The water and 3-WD groups did not differ in paired pulse ratio. All data are 
presented as means ± SEM, significance was accepted at the p < 0.05 level, and n= 5-6 per 
group. * denotes significant differences from the water group. 
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 Figure 5.3. Antalarmin (1.0 µg/ 0.5 µl) attenuated mean binge
and mean BECs (B), but did not alter mean consumption of a sucrose solution (
Correct cannulae placements (i.e., bilateral placements targeting the CeA
blackened circles, and incorrect cannulae placements (i.e., unilateral placements targeting 
the CeA or no placements targeting the CeA) are shown as “X”. All data are presented as 
means ± SEM, significance was accepted at the 
placements per group. * denotes significant differences from the vehicle group.
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-like ethanol consumption (
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p < 0.05 level, and n= 7-9 correct 
A) 
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 CHAPTER 6 
General Discussion 
 
 The CRF system is known to have a significant role in ethanol dependence (Heilig 
and Koob 2007; Lowery and Thiele 2009; Koob 2011), and the novel results of the current 
dissertation demonstrate that this neuropeptide system is also critically involved in binge-like 
ethanol consumption (defined as ethanol consumption resulting in BECs of 80 mg/dl or 
above). The experiments of the current dissertation used the ‘drinking-in-the-dark’ (DID) 
model and a variety of pharmacology, immunohistochemistry, and electrophysiology 
approaches to investigate the role of the CRF system in binge-like ethanol consumption by 
non-dependent C57BL/6J mice. Results revealed that manipulation of the CRF system 
alters binge-like ethanol drinking and that binge-like ethanol consumption alters the 
expression and function of the CRF system. Additionally, the current findings show that CRF 
in the central nucleus of the amygdala (CeA), a brain region critical for ethanol dependence 
(Funk, O'Dell et al. 2006), modulates binge-like ethanol consumption. These results extend 
the current understanding of the role of CRF in ethanol-related behaviors and suggest that 
compounds targeting the CRF system may be effective in attenuating binge drinking prior to 
the onset of ethanol dependence in at-risk clinical populations. 
 The study of the neurobiology of binge drinking has been historically limited by a lack 
of animal models that reliably generate high enough BECs via ethanol self-administration 
(Crabbe, Harris et al. 2011). Most models that are commonly used involve forced exposure 
to high doses of ethanol (Gilpin, Richardson et al. 2008; Gilpin, Smith et al. 2009), which 
may engender different patterns of neural activation than self-administered ethanol. The 
 recently developed DID model that is used in the current dissertation overcomes these 
limitations in that animals voluntarily consume enough ethanol to achieve BECs exceeding 
80 mg/dl (Rhodes, Best et al. 2005; Rhodes, Ford et al. 2007), thus allowing investigations 
of the neurobiology that modulates high levels of ethanol intake as well as the 
neurobiological alterations resulting from high levels of ethanol self-administration. 
Importantly, the DID procedure models aspects of ethanol self-administration that are 
behaviorally distinct from models that generate low to moderate levels of ethanol intake (and 
BECs) as well as from models of ethanol dependence. For example, unlike animals 
consuming low to moderate levels of ethanol, animals consuming ethanol in the DID 
procedure display behavioral signs of ethanol intoxication (Rhodes, Ford et al. 2007). 
Additionally, as shown in the current results, unlike animals consuming ethanol following 
dependence induction (Valdez, Roberts et al. 2002; Breese, Chu et al. 2005; Chu, Koob et 
al. 2007; Sommer, Rimondini et al. 2008), animals consuming ethanol in the DID procedure 
do not display withdrawal symptoms that are indicative of ethanol dependence (i.e., 
increased anxiety-like behavior or ethanol consumption) unless they chronically binge drink 
(i.e., six cycles of DID). 
Summary of the Current Findings 
 Using the DID model, we found that central CRF signaling via CRF1Rs is necessary 
for binge-like ethanol drinking to occur, as a CRF antagonist and a variety of CRF1R 
antagonists delivered centrally or peripherally attenuated binge-like ethanol consumption. In 
agreement with the original study (Sparta, Sparrow et al. 2008), CRF1Rs appear to be 
necessary only for high levels of ethanol drinking that exceed a pharmacologically relevant 
threshold of BECs, as the doses of CRF1R antagonists that effectively attenuated binge-like 
ethanol consumption had no effect on low or moderate levels of ethanol consumption that 
resulted in BECs of 50 mg/dl or lower. These findings parallel those of previous 
investigations showing that CRF1R antagonists protect against elevations of ethanol 
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consumption following dependence induction by exposure to ethanol vapor or to ethanol diet 
but have no effect on ethanol consumption in non-dependent animals (that were exposed to 
air or control diet and do not show elevations of ethanol consumption) (Chu, Koob et al. 
2007; Finn, Snelling et al. 2007; Knapp, Overstreet et al. 2011). As one cycle of binge-like 
drinking does not result in behavioral indices of ethanol dependence, these results are 
among the first to reveal a role for the central CRF system in voluntary ethanol drinking by 
non-dependent animals.  
While manipulations of the CRF system alter binge-like ethanol consumption, it also 
appears that binge-like ethanol consumption alters the CRF system. Using 
immunohistochemistry and a single or multiple exposures to the 4-day DID procedure, we 
investigated the effects binge-like ethanol consumption on CRF expression throughout the 
brain. Significant increases of CRF-IR were observed following only one DID cycle in the 
VTA and following one and six cycles in the CeA. These findings complement the 
pharmacology data by showing that ethanol self-administration by non-dependent animals 
can recruit the CRF system and, furthermore, suggest that extrahypothalamic regions may 
modulate binge drinking behavior. Importantly, both of these brain regions have been 
implicated in drug-taking behavior, as the VTA comprises a major source of dopaminergic 
signaling in the mesolimbic dopamine pathway, a neurocircuit that modulates several 
aspects of reward and reinforcement (Kauer and Malenka 2007), and the CeA is a central 
component of the extended amygdala, a neurocircuit that controls aspects of affect (Koob 
2003).  
Numerous investigations have shown that chronic ethanol exposure alters CRF 
expression in the CeA (Merlo Pich, Lorang et al. 1995; Richter, Zorrilla et al. 2000; Lack, 
Floyd et al. 2005; Funk, O'Dell et al. 2006). In agreement with these investigations, we 
observed elevations of CRF expression in the CeA following chronic binge-like ethanol 
consumption (i.e., six cycles of DID). Notably, after only one episode of binge-like ethanol 
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consumption, we observed elevations of CRF expression of a similar magnitude in the CeA. 
This observation demonstrates for the first time, to our knowledge, that sub-chronic 
exposure to ethanol can significantly alter CRF expression in the CeA.  
The central CRF system modulates a range of behaviors by acting as a 
neuromodulator of other neurochemical systems, including the dopamine system, the 
glutamate system, the serotonin system, and the GABA system (Hauger, Risbrough et al. 
2006). Indeed, CRF receptors are expressed intracellularly in close proximity to 
mitochondria, which may be the mechanism by which CRF alters calcium signaling and 
thereby affects neurochemical release (Jaferi, Lane et al. 2009). Within the CeA, CRF 
enhances GABAergic signaling via CRF1Rs by causing vesicular GABA release (Nie, 
Schweitzer et al. 2004; Nie, Zorrilla et al. 2009). Interestingly, acute ethanol has identical 
effects on GABA signaling and release in the CeA that are also mediated by CRF1Rs (Nie, 
Schweitzer et al. 2004; Nie, Zorrilla et al. 2009). As we observed increases of CRF 
expression in the CeA immediately following binge-like drinking as well as during withdrawal 
from binge-like drinking, we used electrophysiology to determine if CRF-induced GABAergic 
activity was altered by this behavior. Based on previous data comparing ethanol naïve 
animals to animals that were chronically exposed to ethanol vapor (and thus dependent) 
(Roberto, Cruz et al. 2010), we expected to find an enhancement of CRF-induced increases 
of GABAergic activity in animals with a history of binge-like ethanol consumption (3 cycles of 
DID). However, we found that the ability of CRF to enhance GABAergic transmission was 
abolished in animals with a history of binge-like ethanol consumption. Thus, despite 
upregulated CRF expression, CRF’s functional modulation of GABAergic activity was 
disrupted, perhaps reflecting a homeostatic down-regulation of CRF-GABA signaling in the 
CeA. Indeed, as CRF1R signaling is regulated, in part, by CRF itself such that high 
concentrations of CRF desensitize and/or promote internalization of CRF1Rs (Hauger, 
Risbrough et al. 2009), and elevations of CRF expression were noted at the same timepoint, 
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it is possible that CRF-induced down-regulation of CRF1R signaling is responsible for the 
observed null effect on GABAergic signaling. In other words, the homeostatic regulation of 
the CRF-GABA system of the CeA appears to be intact following sub-chronic episodes of 
binge-like ethanol consumption (i.e., 3 cycles of DID). Conversely, following chronic ethanol 
exposure (i.e., via ethanol vapor), such homeostatic mechanisms are believed to fail as 
CRF1R expression is increased and CRF-induced GABAergic activity is enhanced in the 
CeA of dependent animals, perhaps reflecting an allostatic shift in this brain region (Koob 
2003; Roberto, Cruz et al. 2010). In agreement with this hypothesis is the observation that 
dependent animals also show enhanced basal GABAergic activity during withdrawal 
(Roberto, Cruz et al. 2010), an effect that we did not observe in our animals during 
withdrawal from binge-like ethanol consumption. 
To date, this is the only investigation showing that ethanol alters CRF expression in 
the VTA, though previous investigations have shown ethanol-induced alterations in 
excitability of the VTA (Brodie 2002; Appel, Liu et al. 2003; Deng, Li et al. 2009), which may 
be dependent on the CRF system (Wang, Shaham et al. 2005; Tagliaferro and Morales 
2008; Wise and Morales 2010). Though the role of CRF in the VTA in binge-like ethanol 
consumption has not been determined, recent investigations suggest that CRF may 
modulate drug-taking behaviors through interactions with glutamate and dopamine (Wise 
and Morales 2010). Indeed, ethanol-induced changes in dopamine, glutamate and GABA 
signaling have been well-documented (Morikawa and Morrisett 2010) and, importantly, each 
of these neurochemicals are modulated by CRF activity in the VTA (Corominas, Roncero et 
al. 2010; Morikawa and Morrisett 2010). For example, acute exposure to ethanol enhances 
the firing frequency of dopamine neurons in the VTA (Brodie, Shefner et al. 1990), and 
enhances glutamate transmission onto dopamine neurons which increases the release of 
dopamine (Morikawa and Morrisett 2010). Acute ethanol exposure also decreases the firing 
of GABAergic neurons in the VTA, which may also stimulate the excitation of dopamine 
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neurons by disinhibition (Morikawa and Morrisett 2010). Conversely, chronic ethanol 
exposure and withdrawal decreases the firing rates of dopaminergic neurons (Bailey, 
Manley et al. 1998; Shen, Choong et al. 2007), and alters glutamatergic (Stuber, Hopf et al. 
2008) and GABAergic signaling (Morikawa and Morrisett 2010). Because CRF affects each 
of these systems, it is reasonable to hypothesize that some of these changes may be due to 
ethanol-induced alterations in CRF expression (as observed in the current study) and 
function. Indeed, our observation that CRF expression in the VTA was elevated after one 
binge episode but was unaltered following six binge episodes appears to parallel the 
enhancement of dopamine signaling following acute ethanol administration and the 
downregulation of dopamine signaling following chronic ethanol exposure. 
 It is important to note that the effects of binge-like ethanol consumption on CRF 
expression were highly localized to extrahypothalamic brain regions, as changes were not 
observed in the hypothalamus, a region that contains high densities of CRF (Hauger, 
Risbrough et al. 2006). Because it is well-established that upregulation of CRF in the 
hypothalamus and activation of the HPA axis as a whole are observed only following acute 
exposure to ethanol (Richardson, Lee et al. 2008; Lowery and Thiele 2009), it is perhaps 
unsurprising that alterations following binge-like ethanol consumption were not observed. 
Additional pieces of evidence from the current data also argue against a crucial role for the 
HPA axis and/or CRF of the hypothalamus in binge-like ethanol consumption. For example, 
pharmacological or surgical adrenalectomy attenuated both binge-like ethanol consumption 
and sucrose consumption and blockade of the glucocorticoid receptor, a receptor to which 
corticosterone binds, did not alter binge-like ethanol consumption. Likewise, binge-like 
ethanol consumption did not alter corticosterone levels. Perhaps the most convincing 
evidence against a pivotal role for the HPA axis in binge-like ethanol consumption is that 
attenuation of this behavior by a CRF1R antagonist does not require intact HPA axis 
signaling, as the antagonist was as effective in adrenalectomized mice as it was in intact 
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mice. In combination with the findings from the immunohistochemistry experiment, these 
data strongly suggest that, though the HPA axis modulates some aspects of ethanol reward, 
it is not necessary for binge-like ethanol consumption to occur.  
The converging evidence of the current dissertation strongly suggests that binge-like 
ethanol consumption is modulated by CRF signaling in the CeA. To directly assess this 
possibility, we administered the CRF1R antagonist antalarmin into the CeA via site-directed 
microinjections prior to binge-like ethanol consumption and observed significant attenuation 
of this behavior. Therefore, in accordance with our hypothesis, CRF1R signaling in the CeA 
is necessary for the expression of binge-like ethanol consumption by non-dependent 
animals. This novel finding is the first to demonstrate that 1) that CRF1Rs in the CeA are 
involved in ethanol consumption by non-dependent animals so long as the levels of intake 
are high and 2) central CRF1R antagonism attenuates ethanol consumption by either 
dependent or non-dependent animals, as all investigations to date have used central 
administration non-selective CRF antagonists. This finding extends those of previous 
investigations showing that central administration of CRF receptor antagonists into the 
ventricles or the amygdala significantly attenuate ethanol self-administration by dependent 
animals following chronic exposure to ethanol vapor (but have no effect in non-dependent 
animals) (Valdez, Roberts et al. 2002; Funk, O'Dell et al. 2006; Chu, Koob et al. 2007; Finn, 
Snelling et al. 2007). Therefore, binge-like drinking and dependence-induced ethanol 
consumption may be modulated by the same neurocircuitry, CRF signaling in the CeA. 
Together, the results of the current dissertation reveal the following novel 
observations: 1) CRF signaling via the CRF1R is necessary for episodes of drinking that 
yield high BECs (i.e., >80 mg/dl), 2) the extrahypothalamic CRF system is recruited in non-
dependent animals only during episodes of high drinking, in which BECs exceed 50 mg/dl, 
3) recruitment of the CRF system during episodes of drinking that yield high BECs has 
significant consequences on future drinking behavior, perhaps through alterations in CRF 
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expression and function, especially within the CeA, and 4) CRF1R signaling in the CeA 
contributes to high levels of ethanol consumption that results in high BECs even during sub-
chronic ethanol exposure.  
Potential Neurocircuits of Binge-Like Drinking 
Based on our findings, it appears that binge-like ethanol consumption (especially 
initial binges) may be driven by two neurocircuits, the mesolimbic dopamine pathway and 
the extended amygdala. The mesolimbic dopamine pathway regulates many aspects of 
reward, including the reinforcing properties of natural rewards and drugs of abuse, and 
reward-related, motivated behaviors, including drug-seeking behavior. Dopamine release in 
the mesolimbic pathway, and especially within the VTA and the nucleus accumbens, is 
believed to encode information about the rewarding properties of drugs of abuse and 
promote motivated behaviors. Importantly, the dopamine signaling in the VTA and nucleus 
accumbens is regulated by descending projections from the prefrontal cortex (Del Arco and 
Mora 2009; Lodge 2011). Indeed, these systems are often conceptualized in turns of 
stop/go, with the prefrontal cortex providing inhibition (‘stop’) to the ‘go’ circuit of the VTA 
and its downstream targets (Volkow, Wang et al. 2011). CRF modulates dopamine release 
in the VTA by enhancing glutamatergic transmission and dopaminergic projections from the 
VTA cause dopamine release in the nucleus accumbens (Wanat, Hopf et al. 2008; Wise and 
Morales 2009). Current theories of the neurobiology of addiction posit that the early stages 
of drug-taking behavior are motivated by the positive reinforcing effects of the drugs that 
stimulate dopamine signaling in these structures (Kauer and Malenka 2007; Heilig, Thorsell 
et al. 2009; Koob and Volkow 2010; Koob 2011). Indeed, all drugs of abuse including 
ethanol (Katner, Kerr et al. 1996; Brodie, Pesold et al. 1999; Ericson, Molander et al. 2003) 
are known to stimulate dopamine release in this pathway (Kauer and Malenka 2007). Given 
that CRF modulates dopamine release in the VTA (Wise and Morales 2009) and thereby 
may indirectly stimulate dopamine release in the nucleus accumbens (Ding, Rodd et al. 
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2009), it is likely that the increase of CRF expression observed following binge-like ethanol 
consumption alters neurotransmission in these regions (See Figure 6.1). Specifically, 
increases of CRF in the VTA (due to local release from dopaminergic neurons or from CRF 
projections from the BNST, (Corominas, Roncero et al. 2010; Morikawa and Morrisett 2010)) 
could lead to increases of dopamine release within the VTA. Dopaminergic neurons in the 
VTA send projections that promote release of dopamine in the nucleus accumbens and the 
ventral pallidum, two regions which are critical for the performance of reward-related and 
motivated behaviors (Koob and Volkow ; Kauer and Malenka 2007; Smith, Tindell et al. 
2009), and thus affect further drug-taking behavior. Ethanol at high doses (that produce 
BECs in excess of 80 mg/dl) also inhibits neural activity in the prefrontal cortex (Tu, Kroener 
et al. 2007), which may relieve its inhibitory regulation of dopamine release in the VTA and 
nucleus accumbens, adding further drive to the ‘go’ circuit during a binge. Through these 
mechanisms, enhanced dopamine signaling in these regions may promote further ethanol 
intake within a binge episode. Conversely, chronic ethanol exposure leads to a 
downregulation of dopamine signaling in the mesolimbic dopamine pathway (Shen 2003; 
Budygin, Oleson et al. 2007), and similarly, we observed that CRF signaling in the VTA had 
normalized following chronic binge-like ethanol consumption. Thus, if CRF and dopamine 
systems are acting in concert in response to binge-like ethanol consumption, the lack of 
ethanol-induced elevations of CRF expression following chronic binge-like ethanol 
consumption suggests that ethanol is no longer driving binge-like drinking behavior via the 
mesolimbic dopamine pathway.  
CRF of the extended amygdala modulates emotional behaviors, anxiety and affect 
through actions as a neuromodulator in the medial and central amygdala, and the BNST 
(Koob 2003; Heilig, Thorsell et al. 2009; Koob and Volkow 2010). Enhanced CRF activity in 
this neurocircuit following extended exposure to drugs of abuse is hypothesized to underlie 
the distressing withdrawal symptoms which may drive drug-taking behavior during periods of 
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abstinence. Additionally, upregulations of CRF in the extended amygdala that are induced 
by long-term drug exposure appear to enhance stress responsivity (Breese, Chu et al. 2005; 
Koob and Kreek 2007; Koob 2008; Koob 2009), which may also promote increased drug 
taking. Considering the effects of enhanced CRF signaling on drug intake, it is possible that 
the ethanol-induced increase of CRF expression in the CeA observed during binge-like 
ethanol consumption is driving further ethanol intake. The CeA is a complex structure that 
contains many different subdivisions that can be distinguished by the types of neurons they 
contain and their efferent and afferent projections (Cassell, Freedman et al. 1999). The 
majority of central amygdalar neurons are GABAergic, including interneurons that project 
from the lateral to the medial central amygdala, which are proposed to have a significant 
effect on output from this region (Cassell, Freedman et al. 1999). The central amygdala 
projects to many areas of the brain that have been implicated in reward and motivation, 
including the BNST, the paraventricular nucleus of the hypothalamus, the VTA, and the 
lateral hypothalamus (see Figure 6.2; Cassell, Freedman et al. 1999). Additionally, the CeA 
projects to regions that are proposed to facilitate motivated behaviors towards rewarding 
stimuli, including the ventral pallidum (Smith, Tindell et al. 2009) and the substantia nigra 
(Frank and Surmeier 2009; Bryden, Johnson et al. 2011). While the nature of these 
projections from the CeA have not been fully characterized, it is possible that local inhibition 
of GABAergic projection neurons within the CeA due to local GABA activity disinhibits 
downstream regions involved in reward, motivation, and behavioral output (Roberto, Cruz et 
al. 2010). Acute ethanol exposure is known to dose-dependently stimulate GABAergic 
activity in the CeA (persumably, GABAergic interneurons), which may promote inhibition of 
GABAergic projection neurons and thus disinhibit downstream regions (Roberto, Madamba 
et al. 2004). If enough ethanol is consumed to recruit CRF of the CeA (as occurs during 
binge-like ethanol consumption), CRF may compound this effect on GABA signaling, and 
drive further ethanol intake, culminating in a binge. While homeostatic mechanisms appear 
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to regulate the downstream effects of CRF-GABA activity after the binge is terminated (see 
above), it appears that homeostatic mechanisms fail as ethanol misuse becomes chronic 
(Roberto, Cruz et al. 2010). Unlike in the VTA, it appears that the effects of binge-like 
ethanol consumption on CRF in the CeA persist beyond initial binges, suggesting that the 
extended amygdala (and particularly the CeA) is likely a key substrate in the transition to 
alcohol dependence. 
While the mesolimbic dopamine pathway and the extended amygdala are considered 
separate neurocircuits, it is important to note that they have some common projection 
targets and are also connected by indirect and direct projections that are not yet fully 
understood. For example, the CeA projects to the VTA, as does the BNST (Corominas, 
Roncero et al. ; Koob and Volkow 2010). The VTA also has projections to the amygdala, as 
does the nucleus accumbens (Rodaros, Caruana et al. 2007; Haber and Knutson 2009). 
Therefore, it is quite possible that ethanol-induced changes CRF activity in one circuit may 
directly or indirectly alter activity in the other circuit and motivate binge-like drinking 
behavior. 
Before Allostasis 
Unlike the early stages of ethanol use, which are hypothesized to be motivated by 
the positive reinforcing properties of the drug, ethanol use during ethanol dependence is 
hypothesized to be motivated by the negative reinforcing properties of the drug (Koob and 
Kreek 2007; Heilig, Thorsell et al. 2010). As such, ethanol consumption by an ethanol 
dependent individual serves to alleviate symptoms of withdrawal (Koob 2003; Koob 2008). 
Many of these withdrawal symptoms, including increased anxiety and negative affect, are 
due, in part, to dysregulation of the CRF system of the extended amygdala (Heilig and Koob 
2007; Koob 2009). Dysregulation of the CRF system also underlies the marked elevations of 
ethanol consumption that are considered to be characteristic of ethanol dependence. The 
widely accepted allostasis model of alcoholism states that the CRF system is hyperactive 
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during withdrawal from chronic ethanol exposure and that subsequent ethanol consumption 
is motivated by an effort to restore balance (i.e., to down-regulate) to this neurochemical 
system and thereby alleviate the withdrawal symptoms (Koob 2003; Breese, Chu et al. 
2005). Many investigations have identified CRF in the CeA as the key modulator of these 
withdrawal symptoms (Baldwin, Rassnick et al. 1991; Breese, Knapp et al. 2004; Breese, 
Overstreet et al. 2005; Funk, O'Dell et al. 2006; Chu, Koob et al. 2007). Importantly, 
according to the allostasis model, the duration of excessive ethanol exposures and 
withdrawal periods are integral to the recruitment of the CRF system, which is hyperactive 
during withdrawal periods but is down-regulated by ethanol consumption. 
The novel data presented in this dissertation demonstrates that the CRF system can 
be recruited over as little as 4 days of ethanol consumption (which does not result in 
dependence-related behaviors) provided that the levels of ethanol intake are high enough to 
generate significant BECs. Furthermore, the current data shows that binge-like ethanol 
consumption results in significant increases in CRF expression that occur during ethanol 
self-administration and persist into ethanol withdrawal. Together, these data support the 
hypothesis that BECs in excess of a certain threshold recruit the CRF system of the 
extended amygdala, regardless of the length of ethanol exposure and the development of 
ethanol dependence. Indeed, we observed alterations of CRF expression in this region 
following both sub-chronic (i.e., 1 cycle of DID) and chronic (i.e., 6 cycles of DID) binge-like 
ethanol consumption. Furthermore, evidence from studies that induced dependence via 
chronic ethanol vapor or diet exposure may also support this hypothesis, as dependent 
animals consume enough ethanol to achieve BECs of 80 mg/dl or greater during self-
administration periods (Gilpin, Richardson et al. 2008) and also show alterations of CRF 
expression and reductions of ethanol self-administration when treated with CRF antagonists 
(Lowery and Thiele 2009). Thus, it is possible that the CRF system is activated by the 
amount of ethanol consumed during a drinking bout and therefore, BECs exceeding a 
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certain threshold, in addition to or irrespective of the duration of ethanol exposure, may 
recruit the CRF system during ethanol consumption. Moreover, it is possible that once CRF 
is recruited, it stimulates further ethanol intake and leads to excessive, uncontrolled levels of 
consumption that characterize a binge. 
In light of these findings, we propose a new hypothesis that incorporates the novel 
findings of the current work into the well-established allostasis model of alcoholism (Figure 
8). Specifically, during an ethanol binge by a non-dependent individual, we theorize that 
initial ethanol consumption may reduce (point A) or have no effect on CRF signaling in the 
CeA. However, as brain ethanol concentrations increase to a certain threshold (point B), the 
CRF system is recruited and CRF signaling is increased. We hypothesize that upregulated 
CRF signaling that is triggered by sufficient BEC levels during a binge further motivates 
uncontrolled and excessive ethanol consumption, perhaps via a similar mechanism that is 
proposed to motivate uncontrolled dependence-induced drinking (Koob 2003). When the 
ethanol binge ultimately ends (point C), CRF signaling decreases and eventually returns to 
homeostatic levels of signaling (point D). As proposed by Koob and colleagues (Koob 2003), 
as an individual transitions to ethanol dependence, regulatory mechanisms may initially 
allow CRF signaling to return to homeostatic levels (point E), but eventually begin to fail. 
Thus, CRF signaling may remain upregulated for longer durations during ethanol withdrawal 
(point F), but eventually return to homeostatic levels. As the transition to dependence 
continues, CRF signaling is chronically upregulated and no longer returns to homeostatic 
levels (point G), as allostatic set points of CRF signaling are developed through 
neuroadaptations formed in response to repeated high levels of ethanol consumption, as 
demonstrated in numerous elegant experiments (see Koob 2003; Heilig and Koob 2007 for 
review) . Eventually, these neuroadaptations culminate in an ethanol dependent state (point 
H), as suggested by the allostasis model of alcoholism (Koob 2003). 
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In addition to providing insight into how the extrahypothalamic CRF system is 
engaged by high levels of ethanol consumption by non-dependent animals, the results of the 
current study also extend the option of clinical treatment of alcoholism with CRF1R 
antagonists (Lowery and Thiele 2009) to individuals who are binge drinking but do not 
qualify for a diagnosis of alcohol dependence. As such, CRF1R antagonists may be used in 
populations that are at risk for developing alcohol dependence to limit the amount of alcohol 
consumed by individuals during would-be binges. The use of CRF1R antagonists among 
these populations may be especially beneficial in two aspects. First, by limiting binge 
drinking, the likelihood of experiencing the adverse consequences associated with this 
dangerous behavior would be reduced. Second, by targeting the neurocircuitry of alcohol 
dependence using a prophylactic approach, transitioning to an alcohol dependent state may 
be avoided altogether. 
Future Directions 
 The results of the current dissertation provide key insight into the role of CRF in 
binge-like ethanol consumption by non-dependent animals. Future research will examine the 
relationship between CRF activity and dopamine in the VTA as it relates to binge-like 
ethanol consumption. Specifically, follow-up investigations will assess the effects of site-
directed injections of CRF receptor antagonists into the VTA on binge-like ethanol 
consumption using the DID procedure. Additional investigations will explore the permanency 
of changes in CRF expression and function following binge-like ethanol consumption and 
the effects of subsequent binge-like ethanol consumption on this system. Furthermore, the 
effects of binge-like ethanol consumption on CRF’s function will be assessed immediately 
following the termination of the binge (as opposed to 24 h later) to assess the effects of 
ethanol-induced CRF effects on GABAergic transmission in the CeA. Finally, the existing 
literature on the role of CRF in ethanol consumption is largely comprised of studies using 
forced exposure (i.e., ethanol vapor or ethanol diet) to induce dependence, and so direct 
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comparisons between previous reports and the current findings (using a self-administration 
paradigm) cannot be made. Methods of inducing a dependence phenotype via voluntary 
ethanol consumption will greatly inform the current understanding of the role of CRF in 
ethanol-related behaviors. 
 
  
 Figure 6.1. The mesolimbic dopamine pathway under ethanol
conditions. Under naïve conditions, the ‘go’ circuit originating in the VTA is regulated by the 
‘stop’ circuit of the PFC. During binge drinking, the ‘go’ circuit may be activated by ethanol 
(lightning bolt) in two ways: 1) the inhibitory regulation of the PFC is lifted by ethanol’s 
inhibitory effects in this region and 2) ethanol
release in the VTA, NucAcc, and VP. DA release in the NucAcc and the VP may stimulate 
further ethanol drinking behavior by interfacing with motor output regions, culminating in 
uncontrolled ethanol intake in a binge. (PFC, prefrontal cortex
NucAcc, nucleus accumbens; VP, ventral pallidum; CRF, corticotropin
dopamine).   
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 Figure 6.2. The extended amygdala under ethanol
of the medial CeA are not inhibited by interneurons, and thus inhibit downstream targets including the SN and the VP. During 
drinking, the GABAergic interneurons are inhibited by ethanol (lightning bolt) stimulating CRF
signaling in the CeA, thus disinhibiting targets that are downstream of the CeA. By disinhibiting the SN and VP, regions that
reward-related and motivated behaviors by interfacing with motor output regions, ethanol
uncontrolled ethanol intake that culminates in a binge. (CeA, central nucleus of the amygdala; BNST, bed nucleus of the stria
terminalis; LH, lateral hypothalamus; PVN, paraventricular nucleus of the hypothalamus; VTA, ventral tegmental area; SN, substantia 
nigra; VP, ventral pallidum; CRF, corticotropin-
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 Figure 6.3. CRF signaling during an episode of binge drinking, the transition to ethanol dependence, and ethanol dependence. 
Ethanol consumption takes place in bouts, as illustrated in the diagram by the red boxes.
may reduce CRF signaling in the CeA from homeostatic levels (A). As ethanol consumption continues and BECs reach a certain 
threshold (i.e., 80 mg/dl), the CRF system is recruited and CRF signaling increases (B). As the binge ends (C), CRF signaling
decreases because homeostatic mechanisms 
of the transition to ethanol dependence, CRF signaling is recruited during binge
homeostatic mechanisms (E). As the transition to dependence progresses, CRF signaling that is recruited during ethanol 
consumption becomes dysregulated because homeostatic mechanisms fail. CRF signaling remains upregulated during ethanol 
withdrawal (F), but eventually returns to homeostatic levels. 
dependence, the dysregulation of CRF signaling may become permanent due to the development of neuroadaptations in the CRF 
system and the establishment of allostatic set points (G,H). 
1
1
2
 
  Initial ethanol consumption during a binge 
are activated. CRF signaling returns to homeostatic levels (D). During the early stages 
-like ethanol consumption but regulated by 
During the late stages of the transition to dependence and ethanol 
Adapted from Koob (2003). 
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